

# Subject Index

0.08 percent laws. *See* [DWI laws](#)  
0.10 percent laws. *See* [DWI laws](#)  
5-HT. *See* [Serotonin](#)  
5-HT<sub>3</sub> receptors, [96-97](#), [99](#), [100](#)  
5-hydroxytryptamine 3 receptors. *See* [5-HT<sub>3</sub> receptors](#)  
12-step program. *See* [Twelve-step program](#)

## A

A-1 antagonist, [117](#)  
AA. *See* [Alcoholics Anonymous](#)  
Abecarnil, [117](#)  
Abortion, spontaneous, [263](#)  
Abstinence, [358](#), [428](#), [452](#), [455](#). *See also* [Treatment](#); [Relapse](#)  
    animal models and, [111-113](#)  
    anxiety disorders and, [12](#)  
    drug therapy and achieving abstinence, [452-456](#)  
    during pregnancy, [326](#)  
    pituitary adrenal function and, [119](#)  
    Project MATCH, [446](#)  
    recovery from cerebral atrophy and, [138](#)  
    risk of health problems, [15](#)  
Acamprosate, [123](#), [451](#), [454-456](#)  
    abstinence and, [455](#)  
    drug efficacy, [455](#)  
    drug interaction, [455](#)  
    naltrexone and, [455-456](#)  
Accounting costs, [360-361](#). *See also* [Economics](#)  
Acetaldehyde, [224](#), [225](#), [254](#), [277](#)  
    acetaldehyde-protein adducts, [224](#), [225](#), [236](#)  
    malondialdehyde (MAA), [225](#)  
    menstrual cycle and, [275](#)  
    prenatal alcohol exposure and, [302](#)  
Acetaminophen

    animal studies, [205](#)  
    antidote, [205](#)  
    liver toxicity, [205](#)  
    overdose, [205](#)  
    warning labels, [206](#)  
Acetylcholine, [96](#), [136](#)  
    activation of nicotinic receptors, [96](#)  
Acoustic cry analyses, [289-290](#)  
Acquired immunodeficiency syndrome, [215](#), [218](#)  
ACTH. *See* [Adrenocorticotrophic hormone](#)  
Action potentials  
    defined, [70](#)  
    GABA<sub>A</sub> and, [76](#)  
    neurotransmission and, [73](#)  
    voltage-gated ion channels and, [97](#)  
Acute care. *See* [Emergency care](#)  
Acute effects  
    on the brain, [69](#), [89-101](#), [139](#)  
    phosphorylation and, [75](#)  
    protein kinases and, [82](#)  
    synaptic transmission, [78-79](#)  
Adaptation. *See* [Biological adaptation](#)  
Addiction Research Foundation, [406](#)  
Adenocarcinoma, [10](#)  
Adenosine, [82](#), [116](#), [246](#)  
Adenosine triphosphate, [75](#), [98](#), [201](#), [236](#)  
ADH. *See* [Alcohol dehydrogenase](#)  
*ADH2* genes, [169](#), [174](#), [176](#)  
*ADH3* genes, [169](#), [174](#), [176](#)  
ADHD. *See* [Attention deficit-hyperactivity disorder](#)  
Administrative license revocation. *See* [License revocation](#)  
Adolescents  
    alcohol advertising, [374](#), [412-415](#), [418-423](#)  
    alcohol demand, [344-346](#)  
    alcohol expectancies, [189](#), [414](#), [419-421](#), [423](#)

- alcohol use, prevalence, [30](#), [186](#), [345](#), [380](#)  
alcohol-related traffic fatalities, [347](#), [379](#)  
behavioral risk factors, [33-35](#)  
brief intervention and, [434-435](#)  
family-related risk factors for alcohol abuse, [184](#)  
genetic factors in alcohol and tobacco use, [172](#)  
hereditary versus environmental factors, [170-171](#)  
minimum legal drinking age and homicide, [61](#)  
minimum legal drinking age laws, [345](#), [379-381](#)  
peer influences, [171](#), [399](#), [401](#)  
personality development and violence, [57-58](#)  
poor socialization and development of alcohol problems, [183](#)  
preventing and reducing underage drinking, [399-402](#), [404-405](#)  
response to alcohol price change, [344-346](#)  
risk factors for alcohol-related problems in adulthood, [186](#)  
risk versus benefits of alcohol use, [17](#)  
school-based prevention, [399-401](#)  
temperament and, [33-35](#)
- Adrenaline, [244](#), [247](#)  
Adrenocorticotrophic hormone, [114](#)  
Advertising (alcohol). *See* [Alcohol advertising](#)  
Affective disorders. *See also* [Mood disorders](#)  
alcohol-associated risk, [11](#)  
African Americans. *See* [Black Americans](#)  
Aftercare programs, [359](#)  
for women with children with FAS, [330](#)
- Age  
age-related changes in alcohol use, [31](#), [32](#), [35-37](#), [43-44](#)  
drinking and driving by, [377](#)  
impact of a growing aged population, [43-44](#)  
memory processes in drinking behavior by, [190](#)  
probability of alcohol dependence by, [42](#)  
subtypes of alcoholism and, [187](#)
- Age of drinking onset, [33-35](#), [40](#), [41](#)  
risk factors for early onset, [184](#)  
subtypes of alcoholism, [187](#)  
Wernicke-Korsakoff syndrome and, [135](#)
- Aged. *See* [Elderly population](#)  
Aggression. *See* [Aggressive behavior](#)  
Aggressive behavior. *See also* [Violence](#)  
in children and adolescents, [34](#), [35](#)  
relationship to alcohol use, [58](#)
- AIDS. *See* [Acquired immunodeficiency syndrome](#)
- Alaska  
alcohol bans and violence, [60](#), [61](#)
- Alaskan Natives. *See also* [American Indians](#)  
FAS among, [326](#)
- Alcohol abuse  
age of drinking onset, [41](#)  
development over the life span, [35-37](#)  
diagnostic criteria, [11](#)  
economic costs of, [349](#), [364-370](#), [365](#), [366](#)  
external costs, [349](#)  
in adolescents, risk factors, [184](#)  
mental disorders and, [11](#)  
prevalence, [1](#)  
prevention expenditures, [367](#)  
private costs, [349](#)  
related health care cost offsets, [355](#), [358](#)  
violence and, [54-63](#)
- Alcohol advertising, [374](#), [412-423](#)  
consumer awareness, [412](#), [419](#)  
effect on alcohol consumption, [415-418](#)  
effect on traffic fatalities, [416](#)  
frequency and message content, [413](#)  
magazines, [417](#)  
minority populations, [414](#)  
prices of advertising, [416](#)  
television, [413](#), [414](#), [416](#), [419](#), [420](#)
- Alcohol-attributable factor, [5](#)  
Alcohol-attributable fraction, [367-368](#)  
Alcohol availability. *See* [Availability of alcohol](#)  
Alcohol consumption  
advertising and, [412-423](#)  
amounts defined, [3](#)  
by beverage type, per capita, [343](#), [345](#)  
college students, [345-346](#)  
current use in national population, [43](#)  
demographic effects on, [343](#)  
determinants, [343-344](#), [346](#)  
determinants, adolescents, [344](#)  
deterrents [343-346](#)  
homicide and, [60](#)  
marijuana use and, [348-349](#)  
relative risk of death, [241](#)  
trends, [343](#), [345](#)  
violence and, [60-61](#)
- Alcohol control policies, [387-389](#).  
*See also* [Monopoly control](#); [Price of alcohol](#);  
[State](#); [Taxes on alcohol](#)
- Alcohol dehydrogenase, [169](#), [176](#), [254](#), [255](#), [274](#),  
[309-310](#)
- Alcohol demand. *See* [Demand for alcohol](#)
- Alcohol dependence  
age of drinking onset, [40](#), [41](#)  
animal models and, [111](#), [160-166](#)

- brain mechanisms in, [107](#)  
 chronic effects in the brain, [119-123](#)  
 costs of treatment services, [355-361](#)  
 development over the life span, [35-37](#)  
 diagnostic criteria, [7](#), [107](#)  
 familial alcoholism, [181-186](#)  
 gender differences in diagnosis, [41](#)  
 genetic susceptibility [160](#), [171](#), [174](#)  
 impaired workplace and household productivity, [368](#)  
 prevalence, [1](#)  
 probability among alcohol users based on birth year, [42](#)  
 psychosocial factors, [181-191](#)  
 relationship with mental disorders, [11](#)  
 sensitivity as predictive factor, [81](#)  
 tobacco use and, [171-172](#)  
 typologies, [36](#)  
 violence-related trauma, [13](#)
- Alcohol expectancies  
 advertising and, [414-415](#), [419-420](#)  
 children and, [33](#)  
 media literacy and effects on, [420-422](#)  
 role in development of alcohol problems, [189](#)  
 towards alcohol's effects, [189-190](#)
- Alcohol impaired driving. *See* [Drinking and driving](#)
- Alcohol intoxication  
 mechanisms, [78-85](#)  
 NMDA receptors and, [118](#)  
 phosphorylation and, [80-81](#)  
 responsible beverage service and, [404](#)  
 seat belt use and, [390-391](#)  
 symptoms, [69](#)
- Alcohol metabolism. *See* [Metabolism of alcohol](#)
- Alcohol price. *See* [Price of alcohol](#)
- Alcohol-related injury. *See* [Injuries](#)
- Alcohol-related mortality. *See* [Mortality](#)
- Alcohol-related trauma, [399](#), [402-403](#)
- Alcohol-related violence. *See* [Domestic violence; Violence](#)
- Alcohol sales, [374](#), [379-381](#), [389](#), [404-405](#).  
*See also* [Alcohol consumption; Demand for alcohol; Price of alcohol](#)
- Alcohol sales outlets, [388-389](#), [403](#), [404-405](#)  
 density and violence, [59-60](#), [61](#)  
 hours of sale, shortening, [402](#)  
 location, and effect on college students, [346](#)  
 retail versus wholesale, [342](#)
- Alcohol taxes. *See* [Taxes on alcohol](#)
- Alcohol tolerance  
 animal models and, [163](#)  
 brain mechanisms in, [107](#)  
 defined, [69](#), [107](#)  
 GABA<sub>A</sub> receptor subunit expression and, [83](#)  
 neurochemical mechanisms, [121](#)  
 rapid acute tolerance, [80](#), [81](#)  
 relationship with injury severity, [13](#)  
 role of phosphorylation, [80-81](#)  
 sensitivity and, [164](#)
- Alcohol withdrawal syndrome  
 acute, defined and symptoms, [69](#), [113](#)  
 alcohol withdrawal suppression agents, [117](#)  
 animal models in, [111](#)  
 blood pressure and, [247-248](#)  
 emotional/motivational aspects, [116](#)  
 heart rhythm and, [244](#)  
 hyperexcitability and, [139](#)  
 NMDA receptors, [83](#), [84](#)  
 stroke and, [246](#)
- Alcoholic beverages. *See also* [Beer](#); [Wine](#); [Distilled spirits](#)  
 brand, [417-418](#), [419](#)  
 slogan, [419](#)  
 standard drink, [4](#), [430](#)  
 types and role in CHD, [6-7](#)  
 warning labels, [327](#)
- Alcoholic cardiomyopathy, [240-242](#)  
 women's risk, [253](#)
- Alcoholic dementia, [134](#). *See also* [Alzheimer's disease](#)
- Alcoholic hepatitis, [198](#), [199](#), [200](#), [203](#), [216](#)  
 cytokine imbalance and, [199-200](#), [219](#), [222](#)  
 immune system and, [216](#), [217](#), [219](#)  
 neutrophils and, [218](#), [221](#)
- Alcoholic liver disease, [198-204](#), [253](#)  
 acetaminophen toxicity and, [205-206](#)  
 apoptosis and, [200](#)  
 estimated prevalence, [198](#)  
 experimental models of, [201-202](#)  
 hepatitis C and, [206](#)  
 immune disorders and, [214](#), [215](#), [216](#), [217](#)  
 nonalcoholic steatohepatitis and, [206](#)  
 prevention, [202](#)  
 role of cytokines, [198-199](#), [218-219](#)  
 role of fats and fatty acids, [203](#)  
 role of iron, [203-204](#)  
 role of malnutrition, [202-203](#)  
 role of nutrients, [202-204](#)  
 women's risk for, [253](#), [254](#), [255](#), [256](#)
- Alcoholic psychosis  
 genetic susceptibility, [171](#)
- Alcoholics Anonymous, [330](#), [357](#), [359](#), [445-446](#)
- Alcoholism. *See* [Alcohol dependence](#)

- Alcoholism treatment. *See* [Treatment](#)
- Alcohol-related birth defects. *See* [Fetal alcohol effects](#)
- Alcohol-related neurodevelopmental disorders, [286](#), [286](#). *See also* [Fetal alcohol effects](#);
- Alcohol-seeking behavior  
in animal models, [109](#)
- Alcp1*, [164](#)
- Alcp2*, [164](#)
- Aldehyde dehydrogenase, [169](#)
- ALDH. *See* [Aldehyde dehydrogenase](#)
- ALDH2* gene, [169](#)
- ALDH3* gene, [169](#)
- Alleles  
Asian populations, [169](#), [174](#)  
genetic linkage and, [173-174](#)
- Alpha wave activity  
children with prenatal alcohol exposure, [290](#)
- Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate.  
*See* [AMPA](#)
- Alzheimer's disease. *See also* [Alcoholic dementia](#)  
moderate drinking and, [12](#)  
neuron loss, [137](#)  
oxidative stress, [141](#)
- American Indians. *See also* [Alaskan Natives](#)  
dopamine receptor gene, [176](#)  
FAS among, [326](#), [331](#)  
genome scan, [174](#)
- Amino acids  
components of protein, [71](#)  
sequence in GABA, [76](#)  
substitution, [93](#)
- Amnesia, anterograde, [134](#)
- AMPA, [93](#)
- AMPA/kainate receptors, [93-94](#)
- Amygdala, extended, [121](#)  
role in alcohol reinforcement, [113-114](#)
- Anabolic steroids, [203](#)
- Anchoring proteins, [82](#)
- Androgens, [275](#)
- Animal models, [108-113](#). *See also* [Knockout mice](#);  
[Research methodology](#)  
alcohol tolerance, [164](#)  
alcohol-seeking behavior, [109](#)  
genetically engineered mice strains, [303](#), [305](#)  
in vivo and in vitro models, [303](#)  
knockout strains, [147-149](#), [165](#), [303](#)  
loss of righting reflex, [163](#), [164](#)  
mice and rats, [288](#), [303](#), [305-310](#)  
phenotypes, [161](#)  
purpose, [108](#)  
recombinant-inbred strains, [162](#), [163-164](#)  
role in genetic mapping, [162](#)  
role in genetic research, [161-162](#)  
selective breeding, [161-162](#)  
sensitivity to alcohol, [163](#), [164](#)  
transgenic strains, [149](#), [303](#)  
types developed, [107](#)  
validation, [109](#)
- Anions, [74](#)
- ANP. *See* [Atrial natriuretic peptide](#)
- Antidepressants, [451](#), [457-458](#)  
dosage, [458](#)  
metabolism, [458](#)
- Antioxidants, [140](#), [141](#), [199](#), [201](#), [204](#), [236](#), [242](#), [305](#)
- Antisocial behavior  
children and adolescents, [33](#), [34](#)
- Antisocial personality disorder  
familial alcoholism and, [182](#)  
relationship with heavy drinking, [12](#)
- Anxiety disorders. *See also* [Mood disorders](#)  
alcohol-associated risk, [11](#)  
heavy drinking and, [12](#)
- Anxiogenic responses, [116-118](#)
- Anxiolytic effects, [109](#), [116-117](#)
- Apoptosis. *See* [Cell death](#)
- Approach-avoidance behavior, [109](#)
- ARBD. *See* [Fetal alcohol effects](#)
- Arginine vasopressin, [121](#)
- ARND. *See* [Alcohol-related neurodevelopmental disorders](#)
- Arrests, [377](#)
- Arrhythmia, [240](#), [242-244](#). *See also* [Heart function](#)
- Ascites, [202](#)
- Asians. *See also* [Chinese](#); [Japanese](#)  
and alleles, [169](#), [174](#)
- Astrocyte formation  
alcohol effects on, [301](#), [306](#)
- Ataxia, [149](#), [150](#), [164](#)
- ATP. *See* [Adenosine triphosphate](#)
- Atrial fibrillation, [242](#)
- Atrial natriuretic peptide, [248](#)
- At-risk drinking, [427](#), [429](#)
- Attention  
brain lesions and, [137](#)  
deficits, prenatal alcohol-exposed children, [292-293](#)  
sustained, [184](#)

Attention deficit-hyperactivity disorder, [293](#)  
 Attributable risk, [5](#)  
 AUDIT questionnaire, [431](#)  
 Australia. *See also* [International](#)  
   BAC limits, [382-383](#)  
   reducing alcohol-related violence, [407](#)  
 Austria. *See also* [Europe](#); [International](#)  
   BAC limits, [382](#)  
 Autism. *See* [Autistic behavior](#)  
 Autistic behavior  
   prenatal alcohol exposure, [294](#)  
 Autoimmune disorders, [203](#), [214](#), [215-216](#), [225](#)  
 Autopsy reports  
   fetal alcohol syndrome, [287-288](#)  
 Autoreceptors, [149](#)  
 Availability of alcohol. *See also* [Alcohol sales outlets](#)  
   control methods, [387-389](#)  
   geomapping, [405](#)  
   homicide rates and, [61](#)  
   role in violence, [54](#), [59-61](#)  
   underage drinkers, [379-381](#), [401-402](#), [407](#)  
   zoning and, [405](#)  
 Avoidant personality disorder  
   prenatal alcohol exposure and, [294](#)  
 AVP. *See* [Arginine vasopressin](#)  
 Awareness, consumer, [412](#), [419](#)  
 Axons  
   altered formation, [301](#)  
   axon terminals, [72](#), [73](#), [97](#)  
   described, [72](#)  
   serotonin receptors and, [97](#)

## B

Baby boomers, [43](#)  
 BAC. *See* [Blood alcohol concentration](#)  
 Ban  
   alcohol bans and violence, [60-61](#)  
   on alcohol advertising, [416](#)  
 Bars, [58](#), [59](#), [388](#), [403](#), [404](#). *See also* [Restaurants](#);  
   [Social context](#)  
 Bartender. *See* [Server](#)  
 Basal ganglia  
   alcohol effects, [154](#)  
   depiction, [136](#)  
 Basic fibroblast growth factor, [141](#)  
 B-cells, [216-217](#), [218](#), [220](#), [223](#), [236](#)  
   immunoglobulins, [216](#), [217](#), [218](#), [223](#), [237](#)  
 bDNF. *See* [Brain-derived neurotrophic factor](#)  
 Beer. *See also* [Alcoholic beverages](#); [Price of alcohol](#);  
   [Taxes on alcohol](#)  
   advertisements, [413](#), [415](#), [417](#), [419](#), [420](#)  
   prices and effects on alcohol use, [342-346](#)  
   prices and traffic fatality rates and, [346-348](#)  
   taxes and effects on adolescent drinking, [344-346](#)  
 Behavior modification, [397](#)  
 Behavior problems. *See also* [Conduct disorders](#)  
   children and, [33-34](#), [186](#)  
   children of alcoholics and, [182](#)  
   poor parenting and later alcohol problems, [184](#)  
 Behavior scale  
   identifying possible prenatal alcohol exposure,  
     [295](#)  
 Behavioral inhibition  
   children and adolescents, [34](#), [35](#)  
 Behavioral marital therapy, [357](#), [358](#)  
 Behavioral Risk Factor Survey, [375](#)  
 Beliefs about alcohol. *See* [Alcohol expectancies](#)  
 Benefits, economic. *See* [Economics](#)  
 Benefits, health. *See* [Protective effects](#);  
   [Psychosocial benefits](#)  
 BFGF. *See* [Basic fibroblast growth factor](#)  
 Binge drinking  
   adolescents and, [345](#), [347](#)  
   college students and, [345-346](#), [351](#)  
   development of alcohol problems and, [35-36](#)  
   drinking and driving, [375](#)  
   factors affecting, [345-346](#)  
   fetal alcohol effects and, [302](#), [306](#), [307](#), [310](#)  
   gender differences, [36](#)  
   patterns, [35-36](#)  
   risk of injury, [13](#)  
 Biological adaptation  
   cellular, neurochemical, and molecular, [81](#),  
     [115-119](#)  
   neuronal processes, [81](#)  
   role in alcohol tolerance, dependence, and  
     withdrawal, [69](#)  
 Birth defects. *See* [Alcohol-related](#)  
   [neurodevelopmental disorders](#); [Fetal alcohol](#)  
   [effects](#); [Fetal alcohol syndrome](#)  
 Black Americans. *See also* [Racial/ethnic differences](#)  
   age trajectory of alcohol use, [39](#)  
   demographic characteristics, [39](#)  
   drinking and driving, [375](#), [378](#)  
   drinking patterns, [39](#)  
   heavy drinking and, [31](#), [32](#)  
   liver cirrhosis, [9](#)  
   women and risk of hip fracture, [259](#)  
   women, tolerant attitudes, [39](#)  
 Blood alcohol concentration [373](#), [376](#), [382-385](#),  
   [384](#), [432](#). *See also* [DWI laws](#)

- dependent animal models, [111](#)  
 in DWI offenders, [56](#)  
 in homicide offenders, [56](#)  
 international limits, [382-383](#)  
 limits and reducing traffic fatalities, [382-383](#)  
 limits and repeat offenders, [384](#), [385](#)  
 measuring alcohol, [89-90](#)  
 NMDA receptors and, [118](#)  
 traffic fatalities and, [384](#)
- Blood alcohol level. *See* [Blood alcohol concentration](#)
- Blood clotting  
 anticlotting effects of alcohol, [7](#)
- Blood pressure, [240](#), [246-248](#). *See also* [Hypertension](#)  
 alcoholic withdrawal syndrome and, [247-248](#)  
 effects of alcohol, [247-248](#)  
 heavy drinking and, [246](#)  
 J-shaped curve, [248](#)  
 kidney regulation, [248](#)  
 moderate drinking and, [246-247](#)  
 U-shaped curve, [248](#)
- B-lymphocytes. *See* [B-cells](#)
- Bone cells. *See also* [Bone mass](#)  
 alcohol effects, [264-266](#)  
 osteocalcin effect on, [265](#)  
 role of polyamines, [264](#)
- Bone density. *See* [Bone mass](#)
- Bone disease, [197](#), [262](#). *See also* [Osteopenia](#); [Osteoporosis](#)  
 increased risk in postmenopausal women, [259](#)  
 role of nutrition, [262](#)
- Bone mass, [197](#), [258](#), [260](#), [261](#), [262](#), [263](#), [266](#)  
 alcohol effect on adolescent skeletal growth, [262](#), [266](#)  
 gender differences, [260](#)  
 histomorphometry, [261-262](#)  
 hormonal effects on, [263-264](#), [266](#)  
 moderate drinking's protective effect, [260](#), [266](#)  
 pre- and postmenopausal, [260](#), [264](#)
- Brain. *See also* specific parts of the brain; [Central nervous system](#)  
 brain anatomy and structure, [135-138](#), [287](#)  
 brain activity and alcohol effects, [78](#), [82](#)  
 brain activity and brain nuclei, [137](#)  
 brain activity in chronic alcohol use, [69](#)  
 brain development  
 neurobehavioral effects of prenatal alcohol exposure, [289-290](#)  
 neuroimaging techniques, [134](#), [135](#), [287](#), [288](#)  
 NMDA receptors and, [94](#)  
 physical measures of alcohol-altered brain function, [289-290](#), [293](#)  
 prenatal alcohol exposure and, [287-289](#), [301](#), [301-302](#)  
 protein kinase C and, [85](#)  
 size in children with FAS, [287](#)  
 structural damage from prenatal alcohol exposure, [287](#), [287-289](#), [301](#)  
 brain mass, [135](#)  
 degeneration, [136](#)  
 lesions, [137](#)
- Brain abnormalities. *See* [Alcohol-related neurodevelopmental disorders](#); [Fetal alcohol effects](#); [Fetal alcohol syndrome](#)
- Brain anomalies. *See* [Alcohol-related neurodevelopmental disorders](#); [Fetal alcohol effects](#); [Fetal alcohol syndrome](#)
- Brain-derived neurotrophic factor, [141](#)
- Breast cancer, [197](#), [273-278](#). *See also* [Cancer alcohol and tumor initiation and promotion](#), [276-277](#)  
 alcohol-associated risk, [10](#)  
 animal models of, [276](#), [277](#), [278](#)  
 hormone replacement therapy and, [274](#), [275](#), [277](#)  
 influence of hormones on, [274](#), [277](#)  
 mechanisms, [275-277](#), [278](#)  
 moderate drinking and, [275](#)  
 pre- and postmenopausal risk, [274](#), [275](#)  
 risk factors, [274](#), [277](#), [278](#)  
 role of nutrition, [276](#)
- Breath alcohol testing, [384](#), [405](#)
- Brief intervention, [427](#), [432-439](#). *See also* [Counseling](#); [Treatment adolescents and](#), [434-435](#)  
 comparison with lengthy counseling, [435-436](#)  
 components and steps, [432-433](#), [437-438](#)  
 effectiveness, [433-434](#), [435](#), [438](#), [439](#)  
 emergency care and, [434-435](#)  
 family practice settings, [433-434](#)  
 FAS prevention and, [325](#), [330](#)  
 motivational interviews, [436](#)  
 physicians' use of, [438-439](#)  
 special populations and, [436-437](#)  
 college students and, [436](#)  
 elderly population and, [437](#)  
 Mexican Americans and, [437](#)  
 pregnant women and, [436-437](#)  
 strategies for increasing use of, [438-439](#)
- Buffalo Longitudinal Survey of Young Men, [58](#)
- Bupirone, [117](#), [307](#)

## C

- CAGE questionnaire, [329](#), [430-431](#)
- Calcium, intracellular, [83](#), [120](#), [121](#), [139](#)
- Calcium acetylhomotaurinate. *See* [Acamprosate](#)
- Calcium ions  
in neurotransmission, [73](#)
- California  
Administrative license revocation, [381](#)  
alcohol outlet density and violence, [59-60](#)  
Community Trials Project, [402](#)  
DWI law enforcement, [386](#)  
personal intervention for preventing impaired driving, [390](#)  
Victim Impact Panels, [385](#)  
Zero Tolerance law, [381](#)
- California Verbal Learning Test–Children’s version, [291](#)
- cAMP. *See* [Cyclic adenosine monophosphate](#)
- Canada. *See also* [International](#)  
BAC limits, [382](#)  
brief intervention study, [435-436](#)
- Cancer, [9-10](#), [241](#). *See also* [Breast cancer](#);  
[Colorectal cancer](#); [Endometrial cancer](#); [Head and neck cancers](#); [Liver cancer](#); [Pancreatic cancer](#); [Prostate cancer](#); [Stomach cancer](#)
- Cancer Prevention Study II, [8](#), [9](#)
- Carbohydrate-deficient transferrin, [432](#)
- Cardiovascular system. *See also* [Coronary heart disease](#); [Heart disease](#); [Heart function](#)  
alcohol effects, [240-249](#)  
cardiovascular diseases, [4-9](#)
- Caribbean. *See also* [International](#)  
alcohol-associated disability, [17](#)
- Catalase, [140](#)
- Catchment area perspective, [397](#)
- Cations, [74](#)
- Caucasians. *See also* [Racial/ethnic differences](#)  
adolescent response to alcohol advertising, [415](#)  
age trajectory of alcohol use, [39](#)  
alcohol consumption and homicide, [60](#)  
dopamine receptor genes and, [176](#)  
*DRD2* polymorphisms, [176](#)  
drinking and driving, [378](#)  
elderly males, [43-44](#)  
genome scan, [174](#)  
heavy drinking and, [31](#), [32](#), [39](#)  
liver cirrhosis and, [9](#)  
male drinking patterns, [39](#)  
twin studies and genetics of alcoholism, [173](#)  
women, tolerant attitudes, [39](#)
- Causes of alcohol use and dependence.  
*See* [Etiology](#)
- CDT. *See* [carbohydrate deficient transferrin](#)
- Cell adhesion molecules, [199](#), [200](#), [221](#), [225](#), [236](#), [308](#)
- Cell damage, [199](#), [200](#), [300-310](#), [301](#)
- Cell death, [216](#), [219](#), [303-305](#), [306](#)  
apoptosis, [200-201](#), [220](#), [236](#), [264](#), [265](#), [303-305](#), [304](#), [308](#), [309](#), [310](#)  
fetal alcohol syndrome and, [301-305](#), [309-310](#)  
necrosis, [200](#), [238](#), [303](#), [304](#)  
NMDA receptors and, [84](#)  
nitric oxide and, [120](#)  
oxidative stress and, [140](#)
- Cell injury. *See* [Cell damage](#)
- Cell membrane, [72](#), [197](#), [242](#)
- Cell signaling, [176](#), [265-266](#)  
ion channels and, [73](#)  
phosphorylation and, [79](#)  
neuronal excitability, [81](#), [90](#)
- Center for Substance Abuse Treatment, [360](#)
- Central nervous system. *See also* [Brain](#)  
embryonic development, [300](#)  
prenatal alcohol exposure, effects on, [286](#), [300](#), [301](#), [302-308](#)  
structural development, [300](#), [301](#), [302-308](#)
- Cerebellum  
depiction, [136](#)  
nicotinic receptors, [96](#)  
oxidative stress and, [141](#)  
prenatal alcohol exposure, effects on, [288](#)
- Cerebral cortex  
depiction, [136](#)  
oxidative stress and, [141](#)  
prenatal alcohol exposure, effects on, [289](#)
- Cerebrovascular disease. *See also* [Hypertension](#);  
[Stroke](#)  
risks versus benefits of alcohol use [7-8](#)
- Cerebrum  
depiction, [136](#)
- CETP. *See* [Cholesteryl ester transfer protein](#)
- c-fos*, [120](#), [121](#), [153](#), [154](#)
- CHD. *See* [Coronary heart disease](#)
- “Cheap date” strain fruit flies, [165](#)
- Chemical messengers  
formation, [74](#)
- Child Behavior Checklist, [295](#)
- Children. *See also* [Adolescents](#)  
adopted children, [185](#)  
alcohol advertising, [374](#), [412-415](#), [418-423](#)  
alcohol expectancies, [412-413](#), [414](#), [418-422](#)

- behavior problems and adult alcohol use, [33-35](#)
- hereditary versus environmental factors, [170-171](#)
- percent exposed to family alcohol use, [1](#)
- knowledge about alcohol, [31-33](#), [419](#)
- school-based prevention, [399-401](#)
- temperament and later alcohol use, [186](#)
- Children of alcoholics. *See also* [Adolescents](#)
  - development of behavioral problems, [184-185](#)
  - knowledge about alcohol, [32](#)
  - sensitivity to alcohol, [183](#)
  - socialization, [183](#)
  - stress and, [183](#)
  - temperament as a risk factor, [34](#)
- Chimeras, [148-149](#)
- Chimeric receptors, [78](#), [79](#)
- Chinese. *See also* [Asians](#); [Japanese](#)
  - rice wine and mortality, [7](#)
- Chloride ions
  - GABA neurotransmitters and, [76](#)
  - glycine receptors and, [93](#)
- Chloridiazepoxide, [117](#)
- Cholesterol, [245](#), [246](#)
- Cholesteryl ester transfer protein, [245](#)
- Choline, [204](#), [236](#)
- Cholinergic nuclei, [137](#)
- Chronic effects
  - brain and, [69](#), [115](#), [119-123](#), [134-141](#)
  - cAMP distribution, [82](#)
  - memory loss, [84](#)
  - neuronal damage, [69](#)
  - neuronal loss, [69](#)
  - phosphorylation and, [75](#)
  - protein kinases and, [82-83](#)
  - synaptic transmission, [83-85](#)
- chronic Fos-related antigens. *See* [c-fos](#)
- c-jun*, [121](#), [154](#)
- Cladistic analysis, [176](#)
- Client-treatment matching. *See* [Patient-treatment matching](#)
- Clinicians. *See* [Physicians](#)
- CMCA. *See* [Communities Mobilizing for Change on Alcohol](#)
- COGA. *See* [Collaborative Study on Genetics of Alcoholism](#)
- Cognition
  - alcohol effects on, [115](#), [138](#), [188](#)
  - explicit cognition in children, [31](#)
  - explicit versus implicit, [190](#)
  - implicit cognition in children, [31](#)
  - implicit, role in drinking behavior, [190](#)
  - prenatal alcohol exposure, [285](#), [292](#)
  - role in alcohol expectancies, [189-190](#)
- Cognitive behavioral therapy. *See* [Treatment, treatment methods](#)
- Cognitive impairment, [134](#), [138](#)
  - in crime victims, [59](#)
  - testing for, in prenatal alcohol exposure, [290-293](#)
- Cohorts
  - defined, [40](#)
  - probability of alcohol use by, [41](#)
  - probability of alcohol dependence among alcohol users by, [42](#)
- COI. *See* [Cost of illness](#)
- Collaborative Study on Genetics of Alcoholism, [174](#), [176](#)
- Collagen, [198](#), [203](#), [204](#), [236](#), [266](#)
- College Alcohol Study, [345](#)
- College location
  - effect on student drinking, [345](#)
- College students
  - binge drinking, [345-346](#), [351](#)
  - brief interventions, [436](#)
  - determinants of drinking behavior, [346](#)
  - risk for alcohol-related problems, [346](#)
  - State drunk driving laws, effects on drinking among, [346](#)
- Colorectal cancer. *See also* [Cancer](#)
  - alcohol-associated risk, [10](#)
- Communities
  - selection for intervention, [398](#)
- Communities Mobilizing for Change on Alcohol, [399](#), [401-402](#), [407](#)
- Community. *See also* [Prevention](#)
  - coalitions, [402](#), [405](#)
  - community reinforcement approach, [357](#)
  - community-based prevention, [397-408](#)
    - alcohol-related youth violence, [407](#)
    - community mobilization, [407](#)
  - effectiveness, [387](#)
  - methodology, [398-399](#), [406-407](#)
  - reducing drinking and driving, [386-387](#)
  - reducing underage access to alcohol, [401-402](#)
  - homogeneity, [399](#). *See also* [Prevention](#)
- Community Trials Project, [399](#), [402-403](#)
- Comorbidity. *See* [Dual diagnosis](#)
- Computed tomography, [135](#)
- Conditioned preference tasks, [109](#)
- Conduct disorders
  - in children of alcoholics, [184-185](#)

- Conduct problems. *See* [Behavior problems](#)
- Congressional Budget Office, [350](#)
- Consumer behavior  
economic model of, [341](#)
- Consumer response  
alcohol prices or tax changes, [342-351](#), [344](#)
- Co-occurring disorders. *See* [Dual diagnosis](#)
- Coping skills  
protective factor, [185](#)  
coping style and stress reduction, [187](#)
- Coronary heart disease, [240](#), [244-246](#).  
*See also* [Heart disease](#)  
alcohol use and risk of CHD, [3](#), [4-7](#), [240](#), [241](#),  
[244](#)  
angina, [244](#)  
antithrombotic effects of alcohol, [245](#), [246](#)  
heavy/binge drinking and, [244](#)  
moderate drinking and, [4](#), [240](#), [245](#)  
protective mechanisms, [245-246](#)
- Corpus callosum, [136](#), [254](#)  
prenatal alcohol exposure, effects on, [287](#), [288](#)
- Corticotropin-releasing factor, [114](#), [117](#), [119](#), [122](#)
- Cortisol, [114](#)
- Cost measurement systems, [361](#)
- Cost of illness estimates, [364](#)
- Cost of services  
alcoholism treatment, [355-361](#)
- Cost offsets  
alcohol abuse-related health care, [355](#), [358](#)
- Cost research  
methodological tools for conducting, [360-361](#)
- Cost-benefit analyses  
alcoholism treatment modalities, [356-361](#)  
*Cost-Effectiveness in Health and Medicine*, [360](#)
- Costs. *See also* [Economics](#)  
accounting versus economic, [360-361](#)  
private versus external costs, [349](#)
- Counseling, [357](#), [432-439](#), [444-449](#). *See also* [Brief intervention](#); [Treatment](#)  
ancillary, [444](#), [446-448](#)  
brief intervention, [432-439](#)  
brief motivational counseling, [357](#)  
drug therapy and, [451](#)
- Craniofacial anomalies. *See also* [Fetal alcohol effects](#); [Fetal alcohol syndrome](#)  
from prenatal alcohol exposure, [285](#), [286](#),  
[309-310](#)
- Craving, [452](#). *See also* [Priming effects](#)  
animal models and, [111-112](#)  
chronic effect, [69](#)  
sensitization and, [116](#)
- CREB, [120](#)
- CRF. *See* [Corticotropin-releasing factor](#)
- Crime victims. *See also* [Offenders, criminal](#);  
[Violence](#)  
costs to victims of alcohol-related crime, [366](#)  
drinking by, [58-59](#)  
intimate partner versus stranger, [57](#)  
sexual assaults among, [58-59](#)
- Criminal sanctions  
as deterrents to binge drinking, [347](#)
- Cross-price elasticity, [348](#). *See also* [Economics](#);  
[Price elasticity of alcohol](#)
- CT. *See* [Computed tomography](#)
- CTP. *See* [Community Trials Project](#)
- Culture  
role in alcohol use and injury, [13](#)  
role in drinking behavior, [28](#), [39-40](#)  
societies and subcultures, [37-40](#)
- Cyclic adenosine monophosphate  
defined, [74](#)  
protein kinases and, [81-83](#)  
role in sensitivity to alcohol, [165](#)  
tolerance and, [121](#)
- Cytochrome P450 2E1, [140](#), [201](#), [202](#), [204](#), [205](#),  
[224](#), [236](#)
- Cytokines, [216-217](#), [222-223](#), [224](#), [225](#), [265](#).  
*See also* [Interleukins](#); [Transforming growth factor beta](#); [Tumor necrosis factor alpha](#)  
acetaminophen liver toxicity and, [205](#)  
cytokine response in alcohol-fed animals, [207](#),  
[220](#), [222-226](#)  
definition of, [236](#)  
role in alcoholic liver disease, [198-202](#), [207](#),  
[218-219](#)
- Cytoskeleton, [91](#)
- Cytotoxicity, [199](#)
- ## D
- Deaths. *See* [Mortality](#)
- Decision-making  
alcohol expectancies and drinking, [189](#)
- Decoy operations, [404-405](#)
- Demand for alcohol. *See also* [Alcohol consumption](#);  
[Alcohol sales](#)  
adolescents and young adults, [344-346](#)  
age and, [343-346](#)  
alcohol prices and, [342-346](#), [343](#)  
by beverage type, [345](#)  
long-term versus short-term, [344](#)  
theories of, [342-346](#)

- Dementia. *See* [Alcoholic dementia](#)
- Demographic characteristics  
 alcohol consumption and, [343](#), [345](#)  
 elderly, [43](#)  
 sociocultural markers of alcohol problems, [38](#)
- Demographic variables. *See* [Demographic characteristics](#)
- Dendrites, [70](#), [72](#), [73](#), [74](#)
- Deoxyribonucleic acid  
 defined, [70](#), [71](#)  
 genetic recombination, [78-79](#)  
 in gene expression, [153](#)  
 in gene mapping, [161](#)
- Depolarization, [244](#)
- Depression. *See also* [Anxiety disorders](#);  
[Dual diagnosis](#); [Mood disorders](#)  
 comorbid depression, treatment of, [451](#), [457-458](#)  
 prenatal alcohol exposure and, [294](#)  
 primary versus secondary depression, [457-458](#)  
 relapse and, [451](#)
- Designated driver, [389-390](#)
- Desipramine, [457](#)
- Detention facilities, [385](#)
- Deterrence strategies  
 drinking and driving, [346-347](#)
- Developmental perspective  
 defined, [28](#)  
 in etiology of alcohol use and dependence,  
[186-187](#)  
 on alcohol use, [28-45](#)  
 subtype of alcoholism, [187](#)  
 usefulness in alcohol research, [44-45](#)
- Developmental theory. *See* [Developmental perspective](#)
- Developmental trajectories. *See* [Drinking trajectory](#)
- Deviance proneness, [182](#), [183](#), [184](#)
- Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV)*, [109](#)  
*Third Edition, Revised (DSM-III-R)*, [170](#), [173](#),  
[174](#)
- Diazepam, [117](#), [122](#)
- Diencephalon, [136](#)
- Dietary Guidelines for Americans*, [3](#), [6](#), [240](#)
- Dilinoleoylphosphatidylcholine, [204](#), [237](#)
- Disability  
 alcohol-associated disability, [16-17](#)  
 difficulties in quantifying, [16](#)
- Disability-adjusted life years  
 defined, [5](#)  
 global estimates, [16-17](#)
- Distilled spirits. *See also* [Alcohol sales](#);  
[Alcoholic beverages](#); [Demand for alcohol](#);  
[Price of alcohol](#)  
 advertisements and market share, [417](#)
- District of Columbia  
 Zero Tolerance law, [381](#)
- Disulfiram, [357](#), [451](#)
- Dizocilpine. *See* [MK-801](#)
- DLPC. *See* [Dilinoleoylphosphatidylcholine](#)
- DNA. *See* [Deoxyribonucleic acid](#)
- Domestic violence. *See also* [Crime victims](#);  
[Offenders, criminal](#); [Repeat offenders](#);  
[Violence](#)  
 alcohol use by victims, [59](#)  
 alcohol-related, [446](#)  
 effectiveness of marital therapy, [57](#)  
 relationship to alcohol use, [56-57](#)  
 severity of domestic violence, [57](#)
- Dopamine  
 alcohol effects on dopamine release, [99](#)  
 alcohol withdrawal effects, [120](#)  
 defined, [99](#)  
*DRD2* alleles and role in etiology, [169](#)  
 role in reward mechanisms, [114-115](#)  
 serotonin receptors and, [97](#), [456](#)
- Dopamine receptor genes, [152](#), [169](#), [176](#)
- Dopaminergic pathways, [115](#)
- Down syndrome, [290](#)
- DRD2* genes. *See* [Dopamine receptor genes](#)
- Drink. *See* [Standard drink](#)
- Drinking and driving, reducing, [373](#), [375-391](#),  
[405](#). *See also* [Blood alcohol concentration](#);  
[DWI laws](#)  
 alcohol control policies, [387-389](#)  
 beer taxes and traffic fatalities, [346-348](#)  
 college students, State drunk driving laws,  
 effects on consumption, [345-346](#)  
 comprehensive community programs, [386-387](#)  
 enforcement of DWI laws, [386](#)  
 individual actions, designated driver, [389-390](#)  
 individual actions, personal interventions, [390](#)  
 legislative efforts, [378-385](#)  
 safety belt laws, [390-391](#)
- Drinking beliefs. *See* [Alcohol expectancies](#)
- Drinking during pregnancy. *See* [Maternal alcohol consumption](#)
- Drinking frequency. *See* [Quantity-frequency questions](#)
- Drinking patterns. *See also* [Alcohol consumption](#);  
[Binge drinking](#); [Drinking trajectory](#);  
[Low drinking level](#); [Moderate drinking](#)

- alcohol-related birth defects, [306-307](#), [310](#)  
 maternal and fetal alcohol effects and, [302](#)  
 role in CHD, [7](#)  
 young adults, [186-187](#)
- Drinking quantity. *See* [Quantity-frequency questions](#)
- Drinking trajectory. *See also* [Drinking patterns](#)  
 binge drinking trajectories, [35-36](#)  
 defined, [29](#)  
 impact of age of drinking onset, [41](#)  
 over the life span, [35-37](#)  
 role in remission and treatment, [37](#)
- Driving license, [376](#)
- Driving under the influence. *See* [Drinking and driving](#)
- Driving while intoxicated. *See* [Drinking and driving](#); [DWI laws](#)
- Drosophila melanogaster*, [165](#)
- Drug abuse, [359](#), [446](#)
- Drug Abuse Treatment Cost Analysis Program (DATCAP), [360](#)
- Drug discrimination, [100](#), [110](#)
- Drug efficacy  
 nalmefene, [454](#)  
 naltrexone, [453-454](#)
- Drug inhibition. *See* [Inhibitory effects](#)
- Drug interactions  
 acetaminophen and alcohol, [205-206](#)  
 alcohol and tobacco, [171-172](#)  
 in the elderly, [43](#)
- Drug therapy, [451-458](#). *See also* specific drugs;  
[Treatment](#)  
 agents for alcohol withdrawal, [117](#), [119](#)  
 agents for co-occurring disorders, [457-458](#)  
 blocking of kindling effect, [122](#)  
 blocking the reward effect, [452-454](#)  
 reducing alcohol consumption, [119](#), [123](#)  
 relapse prevention, [123](#), [452-455](#)  
 serotonergic agents for alcohol dependence, [456-457](#)
- Drunk driving penalties. *See also* [Drinking and driving](#)  
 effects on drinking, [346](#)
- Dual diagnosis. *See also* [Anxiety disorders](#);  
[Depression](#); [Mood disorders](#)  
 psychiatric, [11-12](#)  
 risk factor in families, [182](#)  
 treatment for patients with, [451](#), [457-458](#)
- DWI laws, [345](#), [378-383](#). *See also* [Blood alcohol concentration](#); [Drinking and driving](#)  
 enforcement, [377](#), [386](#)  
 research methodology, [376](#)
- E**
- Early onset of alcohol use. *See* [Age of drinking onset](#)
- ECF. *See* [Executive cognitive function](#)
- Economics. *See also* [Costs](#)  
 alcohol pricing, [341-354](#)  
 burden of alcohol abuse on society, [365](#), [369-370](#)  
 cross-price elasticity, [348](#)  
 econometric studies, advertising, [412](#), [415-418](#), [422](#)  
 economic benefits of alcohol taxation, [349-351](#)  
 economic costs  
 of alcohol abuse, [1](#), [349](#), [364-370](#), [365](#), [366](#)  
 of alcohol-induced brain damage, [134](#)  
 of alcohol-related motor vehicle crashes, [369](#)  
 of treating alcohol use disorders, [355-361](#), [367](#)  
 of treating medical consequences of alcohol use, [367](#)  
 of varying alcohol treatment modalities, [357](#)  
 to victims of alcohol-related crime, [366](#)  
 economic model of consumer behavior, [341](#)  
 price elasticity of alcohol, [342-344](#), [344](#), [346-347](#)
- EEG. *See* [Electroencephalography](#)
- Effectiveness index, [357](#)
- Elasticity. *See* [Economics](#), [price elasticity](#)
- Elderly population  
 brief intervention and, [437](#)  
 drinking guidelines, [3](#), [240](#)  
 drinking patterns in, [42-44](#)  
 gender differences, [43](#)  
 impact of growing aged population, [43-44](#)  
 liver cirrhosis in, [9](#)  
 male Hispanics, [39](#)
- Electrocardiogram, [243](#), [243](#), [244](#)
- Electroencephalography, [289-290](#)
- Electromyography  
 assessing motor reactions in prenatal alcohol-exposed children, [293](#)
- Embryonic stem cells, [80](#), [148](#)
- Emergency care, brief interventions as part of, [432](#), [434-435](#)
- EMG. *See* [Electromyography](#)
- Emotional disorders. *See also* [Mental health disorders](#)  
 Fetal alcohol syndrome and, [294](#)
- Emotional reactivity, [186](#), [188](#)
- Emotional state. *See* [Emotions](#)

Emotional support, [186](#)  
Emotionality, [182](#), [183](#)  
Emotions, [138](#), [188](#)  
Employee alcohol use  
  excess unemployment, [369](#)  
  lost earnings due to, [369](#)  
  productivity losses due to, [366](#), [368-369](#)  
  workplace accidents and absenteeism, [370](#)  
  work-related effects of, [369-370](#)  
Employee assistance programs, [447](#)  
Employment  
  alcohol industry, factors affecting, [351](#)  
Encephalopathy, [202](#), [203](#). *See also* [Wernicke's encephalopathy](#)  
Endogenous opioids, [452](#)  
Endometrial cancer. *See also* [Cancer](#)  
  alcohol-associated risk, [10](#)  
Endotoxin, [199](#), [201](#), [204](#), [207](#), [218](#), [225](#), [237](#), [255](#)  
Environmental approach. *See* [Public health approach](#)  
Environmental cues, [452](#)  
Environmental factors  
  alcohol and violence, [54](#), [59-63](#)  
  alcohol consumption, [346](#)  
  alcohol use problems in children/adolescents, [28](#), [33-34](#)  
Environmental influences. *See* [Environmental factors](#)  
Epidemiology of Vascular Aging Study, [12](#)  
Estradiol, [254](#), [264](#), [275](#). *See also* [Hormones](#)  
Estrogen, [255](#), [264](#), [275](#). *See also* [Hormones](#)  
Ethnic differences. *See* [Racial/ethnic differences](#)  
Etiology  
  genetics and alcohol dependence, [169](#)  
  psychosocial causes in alcohol dependence, [181-191](#)  
Europe. *See also* specific countries; [International acamprosate](#), [455](#)  
  alcohol advertising studies, [416](#)  
Event-related potentials, [138](#). *See also* [Action potentials](#)  
Evoked potentials. *See* [Event-related potential](#)  
Excise taxes. *See* [Taxes on alcohol](#)  
Excitotoxicity, [139](#), [141](#)  
Executive cognitive function, [138](#).  
  *See also* [Cognition](#)  
  defined, [183-184](#)  
  prenatal alcohol exposure, effects on, [292](#)  
  role in development of alcohol problems, [184](#)  
Exocytosis, [99](#)

Expectancies. *See* [Alcohol expectancies](#)

Expectations. *See* [Alcohol expectancies](#)

Expenditures

  alcohol advertising, [413](#), [415](#)

  alcoholic beverage, [350](#)

External costs of alcohol abuse, [349](#)

## F

Facial features. *See* [Craniofacial anomalies](#)

FAE. *See* [Fetal alcohol effects](#)

Familial alcoholism. *See* [Family history of alcoholism](#)

Family environment

  protective factors in, [185-186](#)

  psychopathology of parents, [182](#)

  role in alcohol problems, [171](#)

  source of stress, [183](#)

Family history of alcoholism. *See also* [Parental alcohol use](#)

  alcohol expectancies, [189](#)

  as a risk factor, [181-186](#)

  stress reduction, [187](#)

Family practice, [433](#)

Fas, [200](#), [237](#)

FAS. *See* [Fetal alcohol syndrome](#)

Fats and fatty acids, [203](#)

Fatty liver, [198](#), [199](#), [203](#), [204](#), [207](#), [216](#), [237](#), [239](#)

FDA. *See* [Food and Drug Administration](#)

Female. *See* [Women](#)

Fetal alcohol effects. *See also* [Alcohol-related neurodevelopmental disorders](#); [Craniofacial anomalies](#); [Fetal alcohol syndrome](#)

  alcohol-induced mechanisms, [301](#)

  amount, duration, pattern, and timing of maternal alcohol exposure and, [302](#)

  description, [285-286](#), [300](#), [324](#)

  diagnosis, [286](#)

  maternal risk factors associated with, [324](#), [324](#)

  neuroanatomical, [285](#), [287-289](#)

  neurobehavioral, [285](#), [289-295](#)

  neurological development, [301](#)

Fetal alcohol syndrome. *See also* [Alcohol-related neurodevelopmental disorders](#); [Children](#); [Fetal alcohol effects](#); [Infants](#); [Maternal alcohol consumption](#)

  alcohol-induced mechanisms, [301](#), [300-310](#)

  alpha wave activity in children with, [290](#)

  amount, duration, pattern, and timing of alcohol exposure and, [302](#)

- assessment tools, [287-295](#)
- attention deficits and, [292-294](#)
- autistic behavior among, [294](#)
- avoidant personality disorder and, [294](#)
- behavioral effects, [285](#)
- brain development and, [301](#)
- central nervous system effects, [285-295](#), [300](#), [301](#), [302-308](#)
- classifications of, [286](#)
- cognitive function and, [285](#), [290-293](#)
- craniofacial anomalies, [285](#), [285](#), [309-310](#)
- crying patterns in infants with, [289-290](#)
- current or past alcohol or other drug use, [294](#)
- depression and, [294](#)
- description, [285](#), [300](#), [368](#)
- diagnostic criteria, [285](#), [286](#), [289](#)
- embryonic development, [300](#)
- emotional disorders, [294](#)
- genetic influences, [302](#)
- growth deficiency, [310](#)
- health care costs associated with, [368](#)
- hyperactivity, [294](#)
- IQ and, [290](#), [295](#)
- learning and memory impairments from, [291](#)
- maternal risk factors associated with, [302](#), [324](#), [328](#)
- medical costs, [368](#)
- mental health, [294](#)
- moderate and low maternal alcohol use and, [291-292](#)
- motor function effects of, [290-291](#), [293](#)
- neuroanatomical effects, [287-290](#)
- neurobehavioral effects of, [289-295](#)
- neuroimaging techniques and, [287](#), [288](#)
- neurological testing of children with, [290](#)
- neuropsychological deficits, [290-291](#)
- obsessive-compulsive disorder and, [294](#)
- premature infants and, [289](#)
- prevalence estimates, [283](#)
- difficulty in determining, [326](#)
- prevention issues, [323-332](#)
- prevention programs and strategies
- aftercare programs, [330](#)
- case management, [330-331](#)
- community-based, [326-327](#)
- comprehensive clinical treatment, [330](#)
- evaluation of, [325-326](#)
- high-risk women and, [326](#), [329-331](#)
- indicated prevention approaches, [329-331](#)
- IOM recommendations, [325](#)
- maternal alcohol consumption and, [323-331](#)
- maternal risk factors and, [324](#)
- methodology and evaluation, [325-326](#)
- professional education, [330](#)
- public education approach, [327](#)
- public health approach, [324](#)
- screening pregnant women for alcohol use, [328-329](#), [329](#), [431-432](#)
- selective FAS prevention approaches, [325](#), [327](#)
- targeting women at risk, [327-329](#), [329](#)
- universal prevention strategies, [325-327](#)
- warning labels on alcoholic beverages, [327](#)
- psychiatric treatment and, [294](#)
- psychosocial effects of, [294-295](#)
- social skills deficits, [295](#)
- speech disorders, [294](#)
- Tourette syndrome, [294](#)
- visual-spatial functioning and, [292](#)
- Fibrosis, [199](#), [203](#), [204](#), [237](#)
- Finland. *See also* [Europe](#); [International](#)
- BAC limits, [383](#)
- Flumazenil, [117](#)
- Fluoxetine, [117](#), [119](#), [456-457](#)
- Food and Drug Administration, [454](#), [455](#)
- Forebrain
- dopaminergic fibers, [99](#)
- dopaminergic pathways, [115](#)
- serotonin receptors, [96](#)
- Fractures, [258-262](#), [266](#)
- falls, [260](#)
- incidence of, [258](#)
- moderate drinking and fracture risk, [259](#), [260](#)
- risk of hip fracture, [258](#)
- black women, [259](#)
- heavy versus light drinkers, [259](#)
- Japanese women, [259](#)
- nonwhite women, [259](#)
- risk of rib fracture, [259](#)
- risk of spinal crush, [259](#)
- Framingham Heart Study, [9](#), [259](#)
- France. *See also* [Europe](#); [International](#)
- acamprosate, [455](#)
- BAC limits, [383](#)
- Epidemiology of Vascular Aging Study, [12](#)
- protective effect of alcohol on dementia, [12](#)
- Free radicals, [140](#), [301](#), [305](#), [309](#). *See also* [Oxidative stress](#); [Reactive oxygen species](#)
- Frontal brain lobe
- degeneration, [136-137](#)
- Fruit flies, genetic studies, [165](#)
- Fyn tyrosine kinase, [80-81](#), [140](#), [152-153](#)

## G

- GABA. *See* [Gamma-aminobutyric acid](#)
- GABA<sub>A</sub> receptors  
 alcohol effects, [78](#), [90-92](#), [101](#), [119-120](#)  
 chronic exposure, [83](#)  
 GABA<sub>A</sub> receptor rho subtype, [79](#)  
 GABA<sub>A</sub> receptor subunit alpha, [91-92](#)  
 GABA<sub>A</sub> receptor subunit beta, [91-92](#)  
 GABA<sub>A</sub> receptor subunit gamma, [91-92](#)  
 genes, [151-152](#)  
 sedative-hypnotics and, [116](#)  
 structure, [76](#)  
 subunit composition, [90](#)
- GABARB1* allele, [174](#)
- Gamma-aminobutyric acid, [76](#), [78](#), [83](#), [90](#)  
 agonists, [114](#), [117](#)  
 antagonists, [113](#)  
 GABAergic neurotransmission, [114-115](#)  
 hyperexcitability, [116](#)  
 role in etiology of alcohol dependence, [174](#)
- Gamma-glutamyltransferase, [432](#)
- Gangliosides, [117](#)
- Gender differences. *See also* [Men](#); [Women](#)  
 alcohol consumption and risk level, [430](#)  
 alcohol dependence diagnosis, [41](#)  
 alcohol metabolism, [254-255](#)  
 alcohol-induced brain damage, [138](#)  
 alcohol-related mortality, [14](#)  
 bone disease, [260](#)  
 brief intervention, effectiveness of, [433](#)  
 drinking and driving, [375](#), [377-378](#)  
 drinking guidelines, [3](#), [240](#)  
 drug metabolism, [458](#)  
 effects of price on alcohol use, [345-346](#)  
 in the elderly, [43](#)  
 in heritability, [170](#)  
 problematic alcohol use, [39](#)  
 responses to alcohol advertising, [414](#), [421](#)  
 risk for developing alcohol-related problems, [430](#)  
 risk of liver cirrhosis, [9](#)  
 risk of peripheral vascular disease, [9](#)  
 risk of stroke, [8](#)  
 WHO brief intervention study, [435](#)
- Gene expression  
 alcohol effects and tumor initiation, [277](#)  
 alcohol effects on molecular regulators, [197](#)  
 altered regulation, [308](#)  
 chronic exposure, [83-85](#), [120](#)  
 defined, [71](#), [153](#)  
 identifying brain areas affected by alcohol, [153](#)  
 regulation, [308](#), [309-310](#)  
 second messengers and, [75](#)
- Gene function  
 QTL mapping and, [165](#)
- Gene identification, [159](#), [160](#), [165](#), [173](#).  
*See also* [QTL mapping](#)
- Gene mapping  
 defined, [160](#), [161](#)  
 false negatives, [163](#)  
 false positives, [163](#)  
 role of animal models, [162](#)
- Gene transcription  
 defined, [70](#), [71](#), [153](#), [239](#)  
 DNA transcription, [75](#)  
 molecular regulators, [223-224](#)
- Gene translation  
 defined, [70](#), [71](#), [153](#)  
 protein kinases and, [82](#)
- General deterrence laws, [376](#), [379-383](#)
- Genes  
 candidates for alcohol-related traits, [149-153](#)  
 dopamine receptor genes, [152](#)  
 Fyn tyrosine kinase genes, [152-153](#)  
 GABA receptor genes, [151-152](#)  
 gene actions, shared, [164-165](#)  
 Insulin-like growth factor genes, [152](#)  
 serotonin receptor genes, [149-151](#)
- Genetic association tests, [175-177](#)
- Genetic linkage  
 defined, [161](#)  
 findings, [173-175](#)  
 research design, [173-174](#)
- Genetic markers, [160](#), [162](#)
- Genetic recombination, [78](#), [79](#).  
*See also* [Recombinant cDNA](#)  
 homologous, [80](#), [148](#)
- Genetic susceptibility  
 alcohol dependence, [160](#), [171](#), [173-175](#)  
 alcoholic psychosis, [171](#)  
 liver cirrhosis, [171](#)
- Genetics  
 animal studies, [90-101](#), [107-123](#), [147-155](#),  
[160-165](#)  
 human studies, [169-177](#)
- Genome scans, [174](#), [175](#)
- Geomapping. *See* [Availability of alcohol](#),  
[geomapping](#)
- Germans  
*DRD2* gene, [176](#)
- Germany. *See also* [Europe](#); [International](#)  
 BAC limits, [383](#)

- GGT. *See* [Gamma-glutamyltransferase](#)
- Glial cells, [134](#), [135](#). *See also* [Neurons](#)
- Global burden of disease, [6](#)
- Global Burden of Disease Study, [16](#), [17](#)
- Glucocorticoids, [119](#)
- Glucose transport and uptake  
  alcohol impairment on, [307-308](#)
- Glutamate, [76](#), [116](#), [121](#), [123](#), [307](#)
- Glutamate receptors, [93-96](#), [120](#)
- Glutathione, [140](#), [200](#), [205](#), [223](#), [237](#)
- Glycine receptors  
  alcohol effects, [78](#), [92-93](#), [101](#)  
  antagonists, [117](#)  
  glycine receptor alpha subtype, [78](#)  
  recombinant, [93](#)  
  various subunits and alcohol effects, [93](#)
- Glycine, [78](#)
- Growth factors. *See also* specific types  
  alcohol's effects on, [305-306](#)  
  defined and role in neurotoxicity, [141](#)
- Growth retardation  
  prenatal alcohol exposure and, [285](#)
- ## H
- Haloperidol, [117](#)
- Haplotype relative risk method, [175](#)
- Haplotypes, [175-176](#)
- Hazardous drinking. *See* [Problematic alcohol use](#)
- HBV. *See* [Hepatitis B virus](#)
- HCV. *See* [Hepatitis C virus](#)
- HDL. *See* [High density lipoprotein cholesterol](#)
- Head and neck cancers. *See also* [Cancer](#)  
  alcohol-associated risk, [9](#)
- Health benefits. *See* [Protective effects](#)
- Health care costs. *See also* [Economics](#)  
  alcoholism treatment, [355-361](#), [427](#)  
  attributable to alcohol abuse, [355](#), [366](#)  
  incurred by alcoholics, [358](#)
- Health care utilization. *See* [Health services research](#)
- Health promotion, [397](#)
- Health Screening Survey, [431](#)
- Health Screening Questionnaire, [431](#)
- Health services research, [339-340](#), [355-361](#)
- Heart attack, [244](#), [245](#), [246](#)
- Heart disease, [197](#), [240-248](#). *See also*  
  [Alcoholic cardiomyopathy](#); [Arrhythmia](#);  
  [Blood pressure](#); [Cardiovascular system](#);  
  [Coronary heart disease](#); [Stroke](#)  
  community based prevention, [397-398](#)  
  coronary artery disease, [240](#)  
  coronary heart disease, [4-7](#), [244-246](#)  
  heart muscle damage, [242](#)  
  cellular and molecular mechanisms, [242](#)  
  ischemic heart disease, [244](#), [246](#)  
  risks versus benefits of alcohol use, [4](#)
- Heart function  
  electrical conduction, [243](#)  
  electrical system, [243](#)  
  heart rhythm, [243-244](#)
- Heavy drinking, [387](#), [452](#)  
  aggression and, [58](#)  
  alcohol associated injuries and violence, [12-13](#)  
  alcohol price increases and, [347-348](#)  
  antisocial personality disorder and, [12](#)  
  anxiety disorders and, [12](#)  
  definition, [3](#)  
  drug therapy and reduction of, [452-454](#), [458](#)  
  effects on cognitive performance, [12](#)  
  liver cirrhosis and, [9](#)  
  mental disorders and, [11-12](#)  
  pregnant women, [329-331](#)
- Hepatic steatosis. *See* [Fatty liver](#)
- Hepatitis B virus, [215](#), [237](#)
- Hepatitis C virus, [204](#), [206](#), [237](#)  
  alcohol abuse and, [215](#)  
  estimated number of people, [206](#)  
  intravenous drug use and, [206](#), [215](#)  
  risk factors, [215](#)  
  unsafe sex practices and, [215](#)
- Hepatocytes, [198](#), [199](#), [200](#), [205](#), [237](#)
- Hereditary versus environmental factors  
  adoption studies, [185](#)  
  alcohol and tobacco use, [171-172](#)  
  in alcoholism, [161](#), [170-171](#), [173](#)
- Heritability  
  of alcoholism, [169-171](#)  
  twin/family studies, [169-173](#)
- Heteroreceptors, [149](#)
- High blood pressure. *See* [Hypertension](#)
- High density lipoprotein cholesterol, [245](#)
- High school students. *See* [Adolescents](#)
- Hindbrain  
  serotonin receptors, [96](#)
- Hippocampus  
  alcohol effects, [114-115](#), [137](#)  
  depiction, [136](#)  
  NMDA receptors and chronic exposure, [83](#), [84](#)  
  sensitivity to alcohol, [153](#)
- Hispanics. *See also* [Latinos](#); [Mexican Americans](#)  
  elderly, [39](#), [44](#)

- drinking and driving, [375](#), [378](#)
  - drinking patterns, [39](#)
  - heavy drinking and, [31](#), [32](#)
  - HIV. *See* [Human immunodeficiency virus](#)
  - Holiday Heart syndrome, [243](#)
  - Homicides
    - alcohol involved, [56](#)
    - racial/ethnic differences, [60](#)
  - Hormones
    - adrenaline and noradrenaline and blood pressure, [244](#), [247](#)
    - alcohol effects, [137](#)
    - estrogens and phytoestrogens, [264](#), [274](#), [275](#)
    - hormonal regulation of bone formation
      - calciotropic hormones, [263](#), [266](#)
      - parathyroid hormone, [263](#)
    - hormone replacement therapy, [274](#), [275](#), [277](#)
    - hormones and alcohol metabolism, [254](#), [255](#), [274](#)
    - insulin-like growth factor and bone remodeling, [265-266](#)
    - insulin-like growth factor and improved immune response, [226](#)
    - leptin and appetite control, [202](#), [207](#)
    - sex hormones, [263](#), [275](#)
    - testosterone, [264](#), [275](#)
  - Hospital costs. *See also* [Economics](#); [Treatment](#)
    - alcohol abuse-related, [368](#)
  - Human genome, [147](#), [159](#), [160](#), [174](#), [177](#)
  - Human Genome Project, [147](#), [160](#), [173](#), [174](#)
  - Human immunodeficiency virus, [206](#), [214](#), [215](#)
  - Hyperactivity, [294](#)
  - Hyperexcitability, [139](#)
  - Hypertension. *See also* [Cerebrovascular disease](#)
    - amount of alcohol use and, [8](#)
    - heavy drinking and, [246](#), [247](#)
    - risk of stroke, [7](#)
  - Hypnosis, alcohol-induced, [92](#)
  - Hypothalamic-pituitary-adrenal axis, [114](#), [119](#)
  - Hypothermia, [149](#), [151](#), [152](#), [164](#)
- I**
- ICD-9. *See* [International Classification of Disease, Ninth Revision](#)
  - IEG. *See* [Immediate early genes](#)
  - IFN-g. *See* [Interferon gamma](#)
  - IGF-I. *See* [Insulin-like growth factor](#)
  - Ignition interlock devices, [383](#)
  - Immediate early genes, [153-155](#)
  - Immune deficiency
    - diseases related to immune deficiency, [214-215](#)
    - hepatitis B, [215](#)
    - hepatitis C, [215](#)
    - human immunodeficiency virus, [206](#), [214](#), [215](#)
    - other infectious diseases, [215](#), [220](#)
    - pneumonia, [214](#), [215](#), [220](#), [225](#)
    - septicemia, [215](#)
    - tuberculosis, [214](#), [215](#), [220](#), [224](#)
  - Immune system
    - alcohol effects, [214-226](#)
  - Immunoglobulins, [217](#), [223](#), [224](#), [237](#)
  - Imipramine, [457](#)
  - Impaired driving. *See* [Drinking and driving](#)
  - Income
    - reduced, and history of alcohol abuse, [369](#)
  - Industrialized nations.
    - disability-adjusted life years, [17](#)
  - Infants. *See also* [Fetal alcohol effects](#);  
[Fetal alcohol syndrome](#)
    - cry patterns in prenatal alcohol exposed, [289-290](#)
  - Inflation-adjusted prices on alcohol, [343](#)
  - Information processing
    - brain lesions and, [137](#)
  - Inhibition. *See* [Behavioral inhibition](#)
  - Inhibitory effects, [80](#), [81](#), [82](#), [94](#), [98](#), [118](#)
  - Injuries. *See also* [Traffic crashes](#)
    - alcohol-associated, [12-13](#), [375](#), [402](#)
    - elderly, [44](#)
    - severity of injury, [57](#)
  - Inpatient care
    - inpatient versus outpatient treatment, [355-356](#), [359](#)
    - treatment costs, [355](#)
  - Institute of Medicine of the National Academy of Sciences, [286](#), [323](#), [325](#), [330](#)
  - Insulin-like growth factor
    - alcohol effects on, during development, [305-306](#)
    - bone remodeling, [265-266](#)
    - defined, [152](#)
    - genes, [152](#)
    - immune response, [226](#)
  - Interferon gamma, [222](#), [226](#), [237](#)
  - Interleukins. *See also* [Cytokines](#)
    - Interleukin-1, [198](#), [199](#), [205](#), [217](#), [218](#), [237](#)
    - Interleukin-4, [222](#), [237](#)
    - Interleukin-5, [222](#)
    - Interleukin-6, [198](#), [201](#), [203](#), [217](#), [218](#), [237](#), [265](#)
    - Interleukin-8, [199](#), [200](#), [217](#), [237](#)
    - Interleukin-10, [200](#), [217](#), [219](#), [222](#), [223](#), [237](#)

Interleukin-12, [217](#), [222](#), [223](#), [226](#), [237](#)

### International

alcohol price and consumption, [346](#)

Australia, [382-383](#), [407](#)

Austria, [382](#)

Canada, [382](#), [435-436](#)

Caribbean, [17](#)

Europe, [416](#)

FAS findings, [323](#), [331-332](#)

Finland, [383](#)

France, [383](#)

Germany, [383](#)

Japan, [383](#)

Latin America, [17](#)

The Netherlands, [383](#)

New Zealand, [33-34](#), [35](#), [419-420](#)

Scotland, [9](#)

South Africa, Republic of, [331](#)

Switzerland, [382](#)

Sweden, [34-35](#), [383](#)

United Kingdom, [382](#), [433](#)

*International Classification of Disease, Ninth Revision*, [171](#)

*International Classification of Impairments, Disabilities, and Handicaps*, [16](#)

Interventions. *See also* [Brief intervention](#)

high-risk women, [329-331](#)

personal interventions, to reduce drinking and driving, [390](#)

Interviews (screening). *See* [Screening instruments](#)

Intoxication. *See* [Alcohol intoxication](#)

Intracellular messengers, [72](#), [74](#), [75](#), [79](#), [81](#)

Intracellular signaling. *See* [Cell signaling](#)

### Ion channels

alcohol effects, [90-98](#), [101](#)

BK channels, [98](#), [101](#)

calcium channels, [97-98](#), [120](#)

ligand-gated, [72](#), [74](#), [76](#), [78](#), [79](#), [90-97](#)

potassium channels, [97](#), [98](#)

proteins, [72-73](#)

sodium channels, [97](#)

voltage-gated, [72](#), [73](#), [97-98](#)

Ion flux, [75](#), [76](#), [93](#), [95](#), [96](#), [97](#), [101](#)

Ions. *See also* specific types

defined, [72-73](#)

cations, [74](#)

anions, [74](#)

neuronal response and, [74](#)

phosphorylation and, [75](#)

sodium ions, [96](#)

potassium ions, [97](#)

Iowa

alcohol sales, [389](#)

IQ scores

prenatally exposed children, [290](#), [295](#)

Iron, [203-204](#)

## J

Japan. *See also* [International](#)

BAC limits, [383](#)

Japanese. *See also* [Asians](#); [Chinese](#)

dopamine receptor genes in, [176](#)

women and risk of hip fracture, [259](#)

Jail, and driving under the influence, [385](#)

## K

Keg registration, [387](#), [402](#)

Kidney disease, [216](#)

Kidney function, impaired, [202](#)

Kindling effect, [120](#), [122](#), [154](#)

*Klebsiella pneumoniae*, [220](#), [225](#)

Knockout mice, [147-149](#). *See also* [Animal models](#)

5-HT<sub>1B</sub> receptor knockout mice, [100](#), [150-151](#)

alcohol tolerance in, [121](#)

FAS research using, [303](#)

Fyn knockout mice, [80-81](#), [152-153](#)

GABA<sub>A</sub> receptor and alcohol effects, [91-92](#)

investigation of candidate genes in, [149-153](#)

procedure for generating knockout mice, [148](#)

Knowledge about alcohol

among children, [30-33](#)

children of alcoholics versus nonalcoholics, [189](#)

Korsakoff's amnestic syndrome. *See* [Korsakoff's psychosis](#)

Korsakoff's psychosis, [134](#), [135](#), [137](#), [138](#)

Kupffer cells, [216](#), [223](#)

acetaminophen liver toxicity and, [205](#)

definition of, [198](#), [238](#)

role in alcoholic liver injury, [199](#), [200](#), [201](#), [202](#), [203-204](#), [218](#), [255](#)

## L

*Lactobacillus*, [202](#)

Latin America

alcohol-associated disability, [17](#)

Latinos. *See also* [Hispanics](#); [Mexican Americans](#)

alcohol advertising and students, [415](#)

Law enforcement, [377](#), [386](#), [404](#)

LDL. *See* [Low density lipoprotein cholesterol](#)  
Learning. *See also* [Cognition](#); [Cognitive impairment](#); [Memory](#)  
brain lesions and, [137](#)  
defects in knockout mice, [81](#)  
hippocampus damage and spatial learning, [137](#)  
in children with FAS, [291](#)  
paired-association learning, [138](#)  
Legal blood alcohol levels. *See* [Minimum legal drinking age laws](#)  
Legal problems  
alcohol-related, [446](#)  
Legislation (drinking and driving). *See* [DWI laws](#);  
[Minimum legal drinking age laws](#)  
Liability  
and insurance rules to reduce binge drinking,  
[347](#)  
License control State. *See* [Privatized alcohol sales outlets](#)  
License revocation, [381-382](#), [405](#)  
License suspension, [377](#)  
Life course. *See* [Life span](#)  
Life span  
drinking over the life span, [28-45](#), [186-187](#)  
Life stage principle  
defined, [42](#)  
Lifestyle  
determinants of alcohol consumption, [343](#)  
Light drinking. *See* [Low drinking level](#)  
Lipid bilayer, [72](#)  
Lipid hydroperoxide, [140](#)  
Lipid peroxidation, [140](#), [200](#), [238](#), [242](#)  
Lipopolysaccharide, [199](#), [218](#)  
Liver cancer, [206](#). *See also* [Cancer](#)  
Liver cirrhosis, [198](#), [204](#), [216](#), [217](#).  
*See also* [Alcoholic liver disease](#)  
genetic susceptibility, [171](#)  
prevalence and mortality, [9](#)  
risk and amount of alcohol, [9](#)  
Liver dysfunction, [455](#), [458](#)  
Liver injury, [201](#), [202](#), [203](#), [205](#), [216](#), [224](#), [255](#)  
Liver regeneration, [201](#)  
Liver transplantation, [205](#), [206](#)  
Location  
of colleges as determinant in alcohol abuse, [345](#)  
Locomotor response, in animals, [152](#), [154](#)  
Longitudinal Alcohol Epidemiologic Survey, [11](#)  
Long-term exposure. *See* [Chronic effects](#)  
Low density lipoprotein cholesterol, [245](#)  
Low drinking level  
definition, [3](#)

pregnant women and attention deficits in  
children, [292](#)  
Luteinizing hormone, [275](#)  
Lymphocytes, [216](#), [217](#), [219](#), [221](#), [226](#), [238](#).  
*See also* [B-cells](#); [T-cells](#); [Natural killer cells](#)

## M

Macrophages, [200](#), [205](#), [216](#), [218](#), [219](#), [220](#), [224](#),  
[238](#)  
Magnetic resonance imaging, [134](#), [135](#)  
visualizing brains of children with FAS,  
[287-289](#)  
Maine  
convicted DWI offender, [383](#), [385](#)  
Major depressive disorder. *See* [Depression](#)  
Male. *See* [Men](#)  
Mammary gland, [275-276](#), [277](#)  
Mandatory treatment, [377](#)  
Marijuana  
alcohol consumption and, [348-349](#)  
Marital violence. *See* [Domestic violence](#)  
Market competition  
alcohol industry and public policy, [342](#)  
Market share, alcohol industry, [417-418](#)  
Maryland  
detention facilities, [385](#)  
DWI punishment, [383](#)  
Massachusetts  
Saving Lives Program, [386](#)  
Zero Tolerance law, [381](#)  
MAST. *See* [Michigan Alcoholism Screening Test](#)  
Matching Alcohol Treatments to Client  
Heterogeneity. *See* [Project MATCH](#)  
Methodology. *See* [Research methodology](#)  
Maternal alcohol consumption, [301-302](#), [323-324](#),  
[431-432](#), [436-437](#). *See also* [Alcohol-related neurodevelopmental disorders](#); [Fetal alcohol effects](#); [Fetal alcohol syndrome](#)  
amount, duration, pattern of drinking, and  
timing, effects on fetus, [301-302](#)  
binge drinking, [302](#), [306-307](#), [310](#), [331-332](#)  
brief intervention and, [436-437](#)  
FAS prevention, [323](#), [331](#)  
risk factors, [324](#), [324-325](#), [328](#)  
Maturation hypothesis, [40](#)  
Mean corpuscular volume, [432](#)  
Media advocacy, of prevention efforts, [403](#),  
[404-405](#)  
Media literacy  
advertising, [412](#), [420-422](#)

- Medical education, [438](#)
- Medication interactions. *See* [Drug interactions](#)
- Medications for treating alcohol use disorders.  
*See* [Drug therapy](#)
- Membrane potential  
  neurotransmission and, [74](#)  
  voltage-gated ion channels and, [97](#)
- Memory  
  brain lesions and, [137](#)  
  defects in knockout mice, [81](#)  
  dysfunction in Korsakoff's psychosis, [134](#)  
  hippocampus damage and, [137](#)  
  memory loss, NMDA receptors and, [78](#), [84](#)
- Memory processes  
  role in drinking behavior, [190](#)
- Men. *See also* [Gender differences](#)  
  alcohol consumption and FAS, [326](#)  
  alcohol consumption and relative risk of death,  
    [241](#)  
  *Alcp1*, [164](#)  
  risk of stroke, [8](#)  
  seat belt use and, [390-391](#)
- Menstrual cycle. *See also* [Women](#)  
  alcohol metabolism and, [254](#)  
  breast cancer risk and, [274](#)  
  moderate drinking and, [275](#)
- Mental health disorders. *See also* [Antisocial  
  personality disorder](#); [Anxiety disorders](#);  
  [Conduct disorders](#); [Depression](#);  
  [Emotional disorders](#); [Fetal alcohol syndrome](#);  
  [Mood disorders](#)  
  in children with FAS, [294](#)
- Messenger ribonucleic acid. *See* [mRNA](#)
- Metabolism of alcohol, [199](#), [224](#), [225](#), [242](#),  
  [254-255](#). *See also* [Acetaldehyde](#); [Cytochrome  
  P450 2E1](#)  
  BAC, absorption, and distribution, [384](#)  
  breast cancer risk, [274](#), [277](#)  
  effects in stress response, [114](#)  
  gender differences, [254-255](#), [275](#)
- Mexican Americans. *See also* [Hispanics](#); [Latinos](#)  
  brief intervention, [436](#), [437](#)
- Mianserin, [117](#)
- Michigan  
  behavioral risk factors in children, [34](#)  
  server training law, [388](#)
- Michigan Alcoholism Screening Test, [329](#)
- Midbrain  
  dopaminergic pathways, [115](#)
- Minimum legal drinking age laws, [345](#), [349](#), [373](#),  
  [376](#), [379-381](#). *See also* [DWI laws](#)  
  effects on teen drinking, [345](#), [379-381](#)  
  effects on traffic fatalities, [379-381](#)  
  enforcement of, [381](#)  
  estimated lives saved by, [380](#)  
  youth homicides and, [61](#)
- Minnesota  
  Communities Mobilizing for Change on  
    Alcohol, [401](#)  
  Project Northland, [399](#)  
  purchase of alcohol by underage youth, [380](#)
- Minority groups, [412](#), [414](#), [418](#). *See also* specific  
  groups
- Minors. *See* [Minimum drinking age laws](#)
- Mitochondria  
  alcohol effects, [200](#), [201](#)  
  defined, [238](#)  
  liver disease and, [204](#)
- MK-801, [117](#), [139](#)
- Moderate drinking. *See also* [Protective effects](#)  
  defined, [3](#), [6](#), [240](#)  
  effects of, [370](#)  
  effects on cognition, [12](#)  
  effects on blood pressure, [247](#), [248](#)  
  guidelines, [3](#), [240](#), [245](#)  
  in the elderly, [43](#)  
  pregnant women and fetal alcohol effects, [291](#)  
  protective effect in coronary heart disease, [6](#), [7](#),  
    [240](#), [245](#)  
  protective effect in ischemic stroke, [246](#)  
  protective effect in dementia, [12](#)  
  role in blood pressure, [8](#)  
  role in stroke, [8](#)
- Monitoring the Future Study, [35](#), [186](#), [344](#), [349](#)
- Monocytes, [216](#), [218](#), [219](#), [220](#), [221](#), [223](#), [238](#).  
  *See also* [Macrophages](#); [Neutrophils](#);  
  [Phagocytes](#)
- Monopoly control, of alcohol sales, [388-389](#).  
  *See also* [Alcohol control policies](#); [Privatized  
  alcohol sales outlets](#); [State](#)
- Mood disorders. *See also* [Anxiety disorders](#);  
  [Depression](#); [Dual diagnosis](#)  
  heavy drinking and, [11-12](#)  
  familial alcoholism and, [182](#)
- Mood enhancement  
  motivating factor to drink, [188](#)
- Morbidity  
  difficulties in quantifying, [16](#)
- Mortality  
  alcohol-related, overall, [13-16](#)  
  alcohol-related traffic deaths, [375-377](#), [378](#),  
    [379](#)

due to liver cirrhosis, [9](#)  
 premature deaths, [369](#)  
 Mothers Against Drunk Driving, [378](#), [391](#)  
 Motivation  
     external motivation, [188-189](#)  
     mood enhancement, [188](#)  
     stress reduction, [187-188](#)  
     to drink, [115-116](#), [187-188](#)  
 Motivational enhancement therapy, [357](#)  
 Motor function impairment  
     in crime victims, [59](#)  
     prenatal alcohol exposure and, [293](#)  
 Motor incoordination. *See* [Ataxia](#)  
 Motor vehicle crashes. *See* [Traffic crashes](#)  
 MR. FIT. *See* [Multiple Risk Factor Intervention Trial](#)  
 MRI. *See* [Magnetic resonance imaging](#)  
 mRNA, [70](#), [71](#), [153](#), [238](#)  
 Multiple drug use  
     alcohol and tobacco, [171-172](#)  
 Multiple Risk Factor Intervention Trial, [397](#)  
 Muscimol, [117](#)  
 Mutagenesis, [79](#)  
 Myelin sheath, [136](#)  
 Myocardial infarction. *See* [Heart attack](#)  
 Myocyte, [242](#), [243](#), [244](#), [246](#)

**N**

*N*-acetylaspartate, [136](#)  
 Nalmefene, [451](#), [454](#)  
 Naloxone, [119](#), [123](#)  
 Naltrexone, [119](#), [123](#), [451](#), [452-454](#)  
     acamprosate and, [455-456](#)  
     drug dose, [453](#)  
     efficacy, [453-454](#)  
     side effects, [453](#)  
 NASH. *See* [Nonalcoholic steatohepatitis](#)  
 National Alcohol and Family Violence Survey, [59](#)  
 National Comorbidity Study, [41](#)  
 National Crime Victimization Survey, [55](#), [56](#), [57](#)  
 National Health and Nutrition Examination Survey, [4](#), [259](#)  
 National Health Interview Survey, [4](#)  
 National Highway Transportation Safety Administration, [386](#)  
 National Household Survey, [39](#)  
 National Human Genome Research Institute, [177](#)  
 National Longitudinal Alcohol Epidemiologic Survey, [11](#), [40](#), [41](#), [368](#)  
 National Longitudinal Survey of Youth, [348](#)

National Longitudinal Study on Adolescent Health, [185](#)  
 National Minimum Drinking Age Act, [379](#)  
 National Mortality Followback Survey, [9](#)  
 National Roadside Survey, [377](#), [389](#)  
 Native Americans. *See* [American Indians](#); [Alaskan Natives](#)  
 Natural killer cells, [217](#), [218](#), [220](#), [221](#), [238](#)  
 NCVS. *See* [National Crime Victimization Survey](#)  
 Necrosis. *See* [Cell death](#)  
 Negative affectivity. *See* [Emotionality](#)  
 Neocortex, [136](#)  
 Neopterin, [199](#)  
 Nerve growth factor, [141](#)  
 Netherlands (The). *See also* [Europe](#); [International BAC limits](#), [383](#)  
     genetic factors in alcohol and tobacco use, [171-172](#)  
 Neural crest cells, [300](#), [309](#)  
 Neuroadaptations, [116-121](#)  
 Neurobehavioral deficits. *See* [Neuropsychological deficits](#)  
 Neuroimaging techniques, [134](#), [135](#), [141](#), [283](#), [285](#), [287-288](#), [288](#), [295](#)  
 Neurological testing  
     fetal alcohol effects, [289-293](#), [288](#), [293](#)  
 Neuronal communication. *See* [Neurotransmission](#)  
 Neuronal death. *See* [Cell death](#); [Necrosis](#)  
 Neuronal excitability  
     nicotinic receptors and, [96](#)  
     NMDA receptors and, [84](#)  
     phosphorylation and, [75](#)  
     withdrawal and, [113](#)  
 Neuronal growth  
     protein kinase C, [85](#)  
 Neurons  
     intoxication and neuron loss, [69](#), [70](#), [137](#)  
     loss of and reduced brain mass, [135](#), [135](#)  
     neural substrates, [113](#), [114](#), [116](#), [121-123](#)  
     postsynaptic, [70](#), [73](#), [74](#), [76](#), [94](#)  
     presynaptic, [70](#), [73](#), [74](#), [97](#)  
     structure and function, [70-75](#), [91](#), [134](#)  
 Neuropsychological deficits, [135](#), [137-138](#)  
     prenatal alcohol exposure and, [285](#), [290-295](#)  
 Neurotoxicity  
     of alcohol, [134-141](#)  
     nitric oxide and, [120](#), [139](#)  
     underlying mechanisms, [138-141](#)  
 Neurotransmission, [73-75](#)  
 Neurotransmitter receptors  
     lipid bilayer, [72](#)  
     synaptic transmission, [73](#), [74](#), [76](#), [78-85](#)

Neurotransmitters. *See also* specific neurotransmitters, e.g., [GABA](#); [Glutamate](#); [Serotonin](#)  
 alcohol's effects on, [118](#), [306-307](#)  
 defined, [73](#), [76](#)  
 medications research and, [451-452](#), [456](#)  
 prenatal alcohol exposure and, [306-307](#)  
 role in neurotransmission, [73-75](#)

Neurotrophin, [141](#)

Neutrophils, [199-200](#), [216-218](#), [221-222](#)  
 alcoholic hepatitis and, [218](#), [221](#)  
 definition, [238](#)  
 role in liver cell injury, [200](#)  
 therapeutic approaches using, [225-226](#)

New Zealand. *See also* [International](#)  
 behavioral risk factors in, [33-34](#), [35](#)  
 alcohol advertising and teenagers, [419-420](#)

NFkB. *See* [Nuclear factor kappa B](#)

NGF. *See* [Nerve growth factor](#)

NHTSA. *See* [National Highway Transportation Safety Administration](#)

Nicotinic receptors, [96](#)

Nitric oxide, [117](#), [120](#), [139](#), [219](#), [246](#)

NK cells. *See* [Natural killer cells](#)

NLAES. *See* [National Longitudinal Alcohol Epidemiologic Survey](#)

NMDA. *See* [N-methyl-D-aspartate](#)

NMDA receptors, [80-81](#), [93-95](#).  
*See also* [Glutamate receptors](#)  
 alcohol's effects on, [96](#), [101](#), [118](#), [122](#), [152](#), [307](#)  
 antagonists, [122](#), [139](#)  
 chronic exposure, [83-84](#), [139-140](#)  
 memory loss, [84](#)  
 phosphorylation and, [140](#)  
 NR1 subunit, [84](#), [93](#), [120](#)  
 NR2 subunit, [84](#), [93](#)  
 NR2A subunit, [84](#), [93](#), [120](#)  
 NR2B, subunit, [80](#), [81](#), [84](#), [93](#), [120](#)  
 NRε2 subunit, [80](#)  
 role in alcohol withdrawal syndrome, [83](#), [119](#), [139-140](#)  
 role in fetal alcohol syndrome, [307](#)  
 role in intoxication and dissociative effects, [118](#)  
 supersensitivity to glutamate, [139-140](#)

N-methyl-D-aspartate, [79](#), [83-84](#)

Nonalcoholic steatohepatitis, [206-207](#), [238](#)

Norepinephrine, [116](#), [121](#), [137](#)

North Carolina  
 alcohol sales, [389](#)

NT-3. *See* [Neurotrophin 3](#)

Nuclear factor kappa B, [199](#), [200](#), [203](#), [204](#), [224](#), [238](#), [277](#)

Nuclei, brain  
 cholinergic nuclei, [137](#)  
 locus ceruleus, [137](#), [154](#)  
 raphe nuclei, [137](#)

Nucleotides, [70](#), [71](#)

Nucleus accumbens  
 dopamine and, [99](#), [122](#), [123](#)  
 prenatal alcohol exposure and, [289](#)  
 reward mechanisms, [113-115](#)

Nurses Health Study, [9](#)

Nutrition  
 malnutrition, [202-203](#), [205](#), [262](#)  
 role in breast cancer, [276](#)

**O**

Obesity, [203](#), [204](#), [206-207](#)

Obsessive-compulsive disorder  
 prenatal alcohol exposure, Tourette syndrome, and, [294](#)

Offenders, criminal. *See also* [Crime victims](#); [Domestic violence](#); [Violence](#)  
 drinking and drug use by, [54](#), [55-57](#)  
 intimate partner versus stranger, [57](#)  
 treatment, [385](#)

Ohio  
 immobilization of vehicles, [383](#)

Older population. *See* [Elderly population](#)

Operant behavior models, [109](#)

Opiate (opioid) antagonists, [119](#), [123](#), [451](#), [452-454](#)

Opioid peptides, [118](#)

Oral preference models, [109](#)

Oregon  
 action against vehicles and tags, [383](#)  
 server training law, [388](#)  
 Victim Impact Panels, [385](#)

Osteoblasts. *See* [Bone cells](#)

Osteopenia, [260-261](#), [262](#), [263](#).  
*See also* [Bone disease](#)

Osteoporosis, [258](#), [259](#), [260](#), [261](#), [262](#), [263](#), [265](#).  
*See also* [Bone disease](#)

Outlet density. *See* [Alcohol sales outlets](#)

Outpatient care  
 treatment costs, [355](#), [368](#)  
 outpatient versus inpatient treatment, [355-358](#), [359](#), [361](#)

Oxidative stress, [140-141](#), [200](#), [201](#), [202](#), [204](#), [238](#). *See also* [Free radicals](#); [Reactive oxygen species](#)

## P

- Pancreatic cancer. *See also* [Cancer](#)  
 alcohol-associated risk, [10](#)
- Parathyroid hormone, [263](#)
- Parental alcohol use. *See also* [Family history of alcoholism](#); [Maternal alcohol consumption](#)  
 effects on children, [182-185](#)  
 paternal alcoholism, [183](#)  
 role of parental support, [186](#)
- Parental support, [186](#)
- Parent-child relations  
 as a protective factor, [185-186](#)  
 as a risk factor, [184-185](#)
- Parenting  
 as a risk factor, [181](#), [183](#), [184](#)  
 genetic influences, [185](#)
- Passenger  
 car, [390](#)
- Patient advice, [429](#), [431](#), [434](#), [435-437](#), [438](#), [439](#), [444](#)
- Patient compliance, [453](#), [454](#)
- Patient costs  
 motivational enhancement therapy, [357](#)
- Patient-treatment matching, [444-445](#)
- Peer influences. *See also* [Sibling influences](#); [Wife](#)  
 adolescent alcohol and tobacco use, [171-172](#), [181](#), [183](#), [184](#), [185](#), [186](#)  
 adolescent alcohol use, [171](#), [399](#), [401](#)  
 motivating factor to drink, [189](#)  
 role of girlfriends in the elderly, [390](#)  
 school failure and peer acceptance, [185](#)  
 socialization and peer acceptance, [185](#)
- Performance review, physicians, [438](#)
- Per se laws, [382](#), [391](#)
- Peripheral vascular disease, [4](#), [9](#)
- Personal intervention. *See* [Interventions](#)
- Personality development  
 role in alcohol use and violence, [13](#), [54](#), [55](#), [57-58](#), [62](#), [63](#)
- Personality Inventory for Children, [294](#)
- Personality traits  
 dopamine receptor genes and, [152](#)
- Phagocytes, [199](#), [216](#), [217](#), [238](#). *See also* [Macrophages](#); [Monocytes](#); [Neutrophils](#)
- Pharmacotherapy. *See* [Drug therapy](#)
- Phosphorylation  
 alcohol effects on protein phosphorylation, [79-85](#)  
 calcium channels and, [98](#)  
 defined, [75](#)  
 GABA receptor genes and, [151](#)  
 GABA<sub>A</sub> subunit makeup, [91](#)  
 receptors, [92](#)
- Physicians  
 performance review, [438](#)  
 Physicians' Health Study, [8](#), [9](#)  
 risk of stroke, [8](#)  
 role in screening, [430-431](#)  
 training, [433](#), [438](#)
- Pituitary-adrenal axis. *See* [Hypothalamus-pituitary-adrenal axis](#)
- PKC. *See* [Protein kinase C](#)
- Pneumonia, [214](#), [215](#), [220](#), [222](#), [225](#)
- Polyamine antagonists, [117](#)
- Polydrug use. *See* [Multiple drug use](#)
- Polyenylphosphatidylcholine, [204](#), [238](#)
- Polymorphism, [199](#)
- Polyunsaturated fatty acids, [140](#)
- PPC. *See* [Polyenylphosphatidylcholine](#)
- Preadolescent. *See* [Children](#)
- Predictive factors. *See also* [Risk factors](#)  
 alcohol expectancies and future alcohol use, [189-190](#)  
 development of alcohol-related problems, [186](#)  
 implicit and explicit cognition, [190](#)
- Predisposition to alcohol dependence.  
*See* [Genetic susceptibility](#)
- Prenatal alcohol exposure. *See* [Alcohol-related neurodevelopmental disorders](#); [Fetal alcohol effects](#); [Fetal alcohol syndrome](#)
- Prevention. *See also* [Alcohol sales outlets](#); [Availability of alcohol](#); [Community-based prevention](#); [School-based prevention](#)  
 approaches, community-based, [373](#), [377](#), [386-387](#), [397-408](#)  
 approaches, effectiveness, [373](#), [374](#)  
 approaches, school-based, [373](#), [399-401](#)  
 deterring repeat DWI offenders, [383-385](#)  
 media literacy, [412](#), [420-422](#)  
 prevention research, local, State, and national levels, [373](#)  
 reducing drinking and driving, [373](#), [375-391](#), [405](#)  
 alcohol control policies, [387-389](#)  
 beer taxes and traffic fatalities, [346-348](#)  
 college students, State drunk driving laws, effects on consumption, [345-346](#)  
 comprehensive community programs, [386-387](#)  
 enforcement of DWI laws, [386](#)  
 individual actions, designated driver, [389-390](#)

- individual actions, personal interventions, [390](#)  
 legislative efforts, [378-385](#)  
 safety belt laws, [390-391](#)  
 reducing injuries and deaths, [402-403](#)  
 reducing underage access to alcohol, [399-402](#), [404-405](#)
- Price of alcohol, [341-352](#), [343](#). *See also* [Economics](#); [Taxes on alcohol](#)  
 binge drinking and, [347](#), [351](#)  
 changes in, [342-343](#), [343](#)  
 consumer response, [342-351](#), [344](#)  
 economic research on, [341-352](#)  
 effect on adolescents, [344-345](#), [349](#)  
 effect on college students, [346](#), [351](#)  
 effect on demand, [342](#)  
 real, adjusted for inflation, [343](#)  
 State influence on, [342](#)
- Price elasticity of alcohol, [342-344](#), [344](#), [347-348](#).  
*See also* [Cross-price elasticity](#); [Economics](#)
- Primary care, [427](#), [430](#), [431](#), [432](#), [433](#), [434](#), [435](#), [437](#), [438](#)
- PRIME-MD questionnaire, [431](#)
- Priming effects, [452](#). *See also* [Craving](#)
- Private costs of alcohol abuse, [349](#)
- Privatized alcohol sales outlets, [388-389](#). *See also* [Alcohol control policies](#); [Monopoly control](#); [State](#)
- Probation, [377](#), [383](#), [385](#)
- Problematic alcohol use, screening for, [427](#), [429-432](#). *See also* [Alcohol abuse](#); [Binge drinking](#); [Heavy drinking](#)
- Productivity  
 losses due to alcohol abuse, [340](#), [364-365](#), [366](#), [368-370](#)  
 losses due to alcohol-related crime, [369](#)  
 losses due to alcohol-related traffic deaths and injuries, [375](#)  
 losses due to premature deaths from alcohol abuse, [369](#)  
 workplace and household, [368](#)
- Project ASSERT, [435](#)
- Project MATCH, [357](#), [445-446](#), [448](#), [454](#)
- Project Northland, [399-401](#)
- Project TrEAT, [433](#)
- Prolonged use of alcohol. *See* [Chronic effects](#)
- Propranolol, [117](#)
- Prostaglandin, [201](#), [239](#)
- Prostate cancer. *See also* [Cancer](#)  
 alcohol-associated risk, [10](#)
- Protective effects. *See also* [Moderate drinking](#)  
 blood pressure, [248](#)  
 bone mass/density, [260-261](#), [266](#)  
 cognitive function and dementia, [12](#)  
 coronary heart disease, [4](#), [16](#), [245](#), [246](#), [248](#)  
 moderate alcohol use, [370](#)  
 of drinking, [3-12](#), [197](#)  
 stress reduction, [11](#)  
 stroke, [8](#), [246](#)
- Protective factors  
 family environment, [185-186](#)  
 role in nonproblematic drinking, [36](#), [37](#)  
 school connectedness, [185](#)
- Protein kinase A, [79](#), [91](#), [98](#), [121](#)
- Protein kinase C, [82](#), [83](#), [85](#), [91](#), [98](#), [120](#), [121](#), [151](#)
- Protein kinases  
 alcohol effects, [79](#), [81-83](#), [85](#)  
 defined, [79](#)  
 Fyn tyrosine kinase, [152](#)  
 localization, [82](#)
- Proteins, [72-73](#), [75](#), [91](#)
- Prozac. *See* [Fluoxetine](#)
- PSAs. *See* [Public service announcements](#)
- Psychiatric disorders. *See also* [Antisocial personality disorder](#); [Anxiety disorders](#); [Conduct disorders](#); [Depression](#); [Dual diagnosis](#); [Mental health disorders](#); [Mood disorders](#)  
 prenatal alcohol exposure and, [294](#)
- Psychopathology  
 of parents and risk of familial alcoholism, [181](#), [182](#)
- Psychosocial benefits, of drinking alcohol.  
*See* [Protective effects](#)
- Psychosocial factors. *See also* [Environmental factors](#); [Family environment](#)  
 in alcohol use and alcoholism, [11](#), [28-45](#), [63](#), [181-191](#)
- PTH. *See* [Parathyroid hormone](#)
- Public health approach, [397](#)  
 preventing FAS, [324](#), [326](#)
- Public Health Services guidelines, [360](#)
- Public policy  
 alcohol prices, effects of, [341-342](#), [347](#)  
 effects on market competition, [342](#).  
*See also* [Alcohol sales outlets](#); [DWI laws](#); [Minimum legal drinking age laws](#)
- Public service announcements/messages  
 antidrinking, [414](#)  
 for designated drivers, [389](#)
- Purkinje cells, [288](#), [306](#)
- PVD. *See* [Peripheral vascular disease](#)

## Q

Quantity-frequency questions, [430-432](#).

*See also* [Screening instruments](#)

QTL. *See* [Quantitative trait loci](#)

QTL mapping

alcohol preference, [163](#), [164](#)

cost and time in verification, [164](#)

defined, [160-161](#)

gene in alcohol consumption, [150](#)

role in genetic research, [162-165](#)

severity of withdrawal symptoms, [151](#)

statistical methods in, [162-163](#)

Quantitative trait loci

alcohol effects on the brain, [147](#)

*Alcp1* and *Alcp2*, [164](#)

defined, [160-161](#)

Quasi-experimental design. *See* [Research methodology](#)

## R

Racial differences. *See* [Racial/ethnic differences](#)

Racial/ethnic differences

alcohol involved homicides, [60](#)

coping with stress, [187](#)

drinking and driving, [375](#), [378](#)

drinking behavior, [31](#), [32](#), [38-40](#)

genetic differences, [174](#)

mood enhancement, [188](#)

naltrexone and, [453](#). *See also* [Alaskan Natives](#); [American Indians](#); [Asians](#); [Black Americans](#); [Hispanics](#); [Latinos](#); [Mexican Americans](#)

RBS. *See* [Responsible beverage service](#)

Reactive oxygen species, [199-200](#), [224](#), [242](#), [277](#).

*See also* [Free radicals](#); [Oxidative stress](#)

acetaminophen liver toxicity and, [205](#)

in alcohol-induced liver injury, [201](#), [202](#), [203](#), [224](#)

definition, [239](#)

Reasons for drinking. *See* [Motivation](#)

Receptors. *See also* [Neurotransmitter receptors](#)

defined, [239](#)

localization, [91](#)

postsynaptic, [99](#)

presynaptic, [99](#), [149](#)

Recidivism, [383](#), [385](#)

Recombinant cDNA, [90](#)

Recombinant complementary DNA.

*See* [Recombinant cDNA](#)

Recombinant glycine receptors, [93](#)

Recovery from alcoholism. *See* [Treatment](#)

Regulations

alcohol advertising, [412](#), [416](#)

Reinforcement, [99](#), [100](#), [107-113](#), [109](#), [116](#), [118](#), [119](#), [150](#), [452](#). *See also* [Motivation](#)

Relapse

animal models and, [111-113](#), [122-123](#)

defined, [112](#)

neurobiological mechanisms, [122-123](#)

prevention therapy, [358](#), [452-455](#)

Project MATCH, [446](#)

risk, [451](#), [453](#), [454](#)

risk and acamprosate, [454-455](#)

risk due to untreated depression, [457](#)

Remove Intoxicated Drivers, [378](#)

Repeat offenders. *See also* [Offenders, criminal](#)  
dedicated detention, [385](#)

laws to deter, [378-379](#), [383](#), [385](#)

probation, [385](#)

treatment for, [385](#)

Victim Impact Panels, [385](#)

Research methodology

alcohol advertising effects, [412](#), [414-418](#), [420](#), [421-422](#)

animal models

alcohol-seeking behavior, [109](#)

alcohol tolerance, [164](#)

loss of righting reflex, [163](#), [164](#)

and prenatal alcohol exposure, [288](#), [303](#), [305](#), [306](#), [309-310](#)

bone histomorphometry, [261-262](#)

cell cultures for studying FAS defects, [303](#)

effectiveness of DWI laws and programs, [376](#)

electrophysiology, [99](#)

experimental studies and advertising, [412](#), [414-415](#), [422](#)

genetic association studies, design of, [175-177](#)

genetically engineered mice, [303](#), [305](#)

in study of alcohol-related violence, [55](#)

in study of risk, [5-6](#)

in vitro and in vivo models for studying FAS, [303](#)

in vivo voltammetry, [99](#)

interval mapping, [162-163](#)

knockout strains, [147-149](#), [148](#), [165](#), [303](#)

microdialysis, [89](#), [99](#)

neuroimaging techniques, [134](#), [135](#), [287-288](#), [288](#)

prevention studies

community-based approaches, [398-399](#), [407](#)

drinking and driving, [376](#)  
 fetal alcohol syndrome, [325-326](#)  
 quasi-experimental design, [376](#)  
 recombinant inbred strains, [162](#), [163-164](#)  
 selective breeding of mice and rats, [161](#), [303](#)  
 self-selection, [358](#)  
 statistical methods in gene mapping, [162-163](#)  
 survey studies and advertising effects, [412](#),  
[418-420](#), [422](#)  
 time lags in stress studies, [188](#)  
 time-series design, [376](#)  
 transgenic mice and rats, [149](#), [303](#)  
 treatment costs, [356](#), [360-361](#)  
 twin/family studies in genetics, [169-173](#)  
 Responsible beverage service, [402](#), [403](#), [404](#).  
*See also* [Server](#)  
 Restaurants, [388](#), [403](#), [404](#). *See also* [Bars](#);  
[Social context](#)  
 Restrictions. *See* [Regulations](#)  
 Retionic acid, [309-310](#)  
 ReVia. *See* [Naltrexone](#)  
 Reward thresholds, [113](#)  
 Reward, [97](#), [99](#), [100](#), [107-108](#), [113-115](#), [118](#),  
[119](#), [122](#), [150](#), [452-454](#)  
 Ribonucleic acid. *See* [RNA](#)  
 Ribosomes, [71](#)  
 Righting reflex  
   insulin-like growth factor genes and, [152](#)  
   loss of, in animal models, [163](#), [164](#)  
   loss of, in knockout mice, [151](#)  
 Risk  
   alcohol-related problems and adolescents, [351](#)  
   defined, [5](#)  
   research methodology, [6](#)  
   types of, [5](#)  
   versus benefits of drinking, [3-12](#)  
 Risk factors. *See also* [Predictive factors](#)  
   adolescents, [33](#)  
   family environment, [184-185](#)  
   family history of alcoholism, [181-182](#)  
   genetic, [170](#), [171](#)  
   heavy drinking in adolescents, [186](#)  
   hepatitis C, [215](#)  
   maternal, associated with FAS, [324](#)  
   obesity and alcoholic liver disease, [203](#)  
   poor parenting, [184-185](#)  
   sensitivity to alcohol, [161](#)  
 Risk moderators. *See also* [Protective factors](#)  
   alcohol expectancies, [189-190](#)  
 Risk-taking behavior, [185](#)  
 Ritanserin, [117](#), [456](#)

RNA  
   defined, [70](#)  
   NMDA receptors and, [84](#)  
   Protein kinase C, [85](#)  
   transcription, [70](#), [71](#)  
   translation, [70](#), [71](#)  
 Roper Organization, [389](#)  
 ROS. *See* [Reactive oxygen species](#)  
 Rutgers Health and Human Development  
   Project, [58](#)

## S

*S*-adenosyl-L-methionine, [204](#), [239](#)  
 Safety belts. *See* [Seat belts](#)  
 Sales of alcohol. *See* [Alcohol sales](#)  
 SAM. *See* [S-adenosyl-L-methionine](#)  
 Saving Lives Program, [386](#)  
 School-based prevention programs, [399-401](#).  
*See also* [Prevention](#)  
 Scotland. *See also* [Europe](#); [International](#);  
[United Kingdom](#)  
   prevalence of peripheral vascular disease, [9](#)  
 Screening, [429-439](#). *See also* [Brief intervention](#);  
[Treatment](#)  
   at-risk women, [328](#), [329](#)  
   prenatal alcohol-exposed individuals, [295](#)  
   problem drinking, [328](#), [329](#), [429-439](#)  
 Screening instruments  
   interviews, [430](#)  
   laboratory tests, [432](#)  
     carbohydrate-deficient transferrin assay, [432](#)  
     gamma-glutamyltransferase, [432](#)  
     mean corpuscular volume, [432](#)  
   questionnaires, [430-432](#)  
     AUDIT questionnaire, [431](#)  
     CAGE questionnaire, [430-431](#)  
     Health Screening Questionnaire, [431](#)  
     Health Screening Survey, [431](#)  
     PRIME-MD questionnaire, [431](#)  
     T-ACE questionnaire, [431-432](#)  
     Trauma Scale questionnaire, [431](#)  
     TWEAK questionnaire, [431-432](#)  
   sensitivity, [429](#)  
   specificity, [429](#). *See also* [Brief intervention](#);  
     [Quantity-frequency questions](#); [Treatment](#)  
 Seat belts, [375](#), [390-391](#)  
 Second messengers  
   defined, [72](#), [74](#)  
   protein kinases and, [81-83](#)  
   sensitization and, [122](#)  
   various functions, [75](#)

- Sedative-hypnotic drugs, [118](#)  
 Sedative-hypnotic effect  
   in knockout mice, [92](#)  
 Seizures, [122](#)  
 Selective breeding, [110](#), [161](#)  
 Selective disinhibition theory, [61-62](#)  
 Selective serotonin reuptake inhibitors, [119](#), [151](#),  
   [456-458](#). *See also* [Serotonin](#)  
 Self medication, [456](#)  
 Self-administration, in animals, [110](#), [111-113](#)  
 Self-control training, [357](#)  
 Self-regulation, [183-184](#), [186](#)  
 Sensation-seeking behavior  
   motivating factor in drinking, [188](#)  
 Sensitivity to alcohol  
   as a risk factor, [161](#)  
   in animal models, [163](#), [164](#)  
   in children of alcoholics, [183](#)  
   in familial alcoholism, [182](#), [183](#)  
   Fyn tyrosine kinase genes and, [152](#)  
   GABA<sub>A</sub> receptors, [91-92](#)  
   predictive factor, [81](#)  
   receptors and, [79](#)  
   relationship to tolerance, [164](#)  
   rewarding effects and amount of drinking, [100](#)  
   role of cAMP, [165](#)  
   voltage-gated ion channels and, [97-98](#)  
 Sensitization  
   defined, [116](#)  
   glucocorticoids and, [119](#)  
   immediate early gene expression and, [154](#)  
   neurochemical mechanisms, [122](#)  
 Sentencing, impaired-driving offenses, [386](#)  
 Serotonergic agents, [456-457](#)  
 Serotonin, [96](#), [118-119](#), [456](#). *See also* [Selective serotonin reuptake inhibitors](#)  
   agonists, [99-100](#)  
   antagonists, [100](#)  
   prenatal alcohol exposure, effect on, [306-307](#)  
 Serotonin receptors, [96-97](#), [118-119](#)  
   antagonists, [117](#), [456](#)  
   genes, [149-151](#)  
 Sertraline, [456](#), [457-458](#)  
 Server. *See also* [Responsible beverage service](#)  
   server liability, [388](#)  
   server sanction, [388](#)  
   server training, [388](#), [403](#), [404](#)  
 Sexual assault. *See also* [Domestic violence](#);  
   [Violence](#)  
   accompanying injury, [57](#)  
   drinking by victim, [58-59](#)  
 Short Alcohol Dependence Data Questionnaire,  
   [432](#)  
 Short Michigan Alcoholism Screening Test, [432](#),  
   [434](#)  
 Sibling influences. *See also* [Peer influences](#)  
   on adolescent alcohol use, [185](#)  
 Signal transduction, [74](#)  
 Signaling pathways, [304](#). *See also* [Cell signaling](#)  
   bone cells and, [265](#)  
   heart muscle damage and, [242](#)  
   immune response and, [223](#), [224](#)  
 Skeletal system  
   alcohol effects, [258-266](#)  
 S-MAST. *See* [Short Michigan Alcoholism Screening Test](#)  
 Sobriety checkpoints, [386](#), [405](#)  
 Social context  
   bar characteristics and violence, [59](#)  
   role in drinking behavior, [37-40](#)  
 Social networks, [445](#), [446](#), [447-448](#)  
 Social norms  
   acceptability of alcohol use, [186-187](#), [402](#)  
   motivating factor in drinking, [188-189](#)  
   relationship with alcohol-related violence,  
     [61-62](#)  
 Soma, cell, [70](#), [72](#), [73](#)  
 South Africa, Republic of, [331](#).  
   *See also* [International](#)  
 Special populations. *See* [Alaskan Natives](#); [American Indians](#); [Black Americans](#); [Hispanics](#); [Latinos](#);  
   [Mexican Americans](#)  
 Specific deterrence laws, [376](#), [383](#), [385](#)  
 Sport sponsorship  
   alcohol advertising, [413](#)  
 Sports programming  
   alcohol advertising, [413](#), [414](#)  
 SSRI. *See* [Selective serotonin reuptake inhibitors](#)  
 Standard drink, [4](#), [430](#). *See also* [Alcoholic beverages](#)  
 State  
   influence on alcohol prices, [342](#)  
   monopoly control of alcohol sales, [388-389](#)  
 Statistics. *See also* [Expenditures](#)  
   alcohol and drug use by offenders, [55-56](#)  
   alcohol consumption and prices, [343](#), [343](#)  
   alcohol involvement in crime, [54](#), [56](#)  
   alcohol-associated disability, [16-17](#)  
   alcohol-dependents with brain disorders, [134](#)  
   alcoholic liver disease, prevalence, [198](#)  
   alcohol-impaired drivers, [375](#), [377-378](#), [378](#),  
     [379](#)  
   alcohol-related homicides, [56](#)

- alcohol-related, overall mortality, [14-16](#)  
alcohol-related traffic accident victims, [375](#)  
alcohol-related traffic injuries, [375](#)  
alcohol-related traffic mortality, [44](#), [375](#), [378](#),  
[379](#), [387](#), [416](#)  
current alcohol use in the elderly, [43](#)  
current national alcohol use, [43](#)  
drinking among adolescents, [36](#), [186](#), [349](#)  
drinking among college students, [345](#)  
drinking among high school seniors, [186](#), [344](#)-  
[345](#), [349](#), [380](#)  
drinking and driving by age groups, [377](#)  
drinking and driving by gender, [377](#)  
drinking and driving by racial/ethnic group,  
[378](#)  
DWI arrests, [375](#)  
economic costs of alcohol abuse, [1](#), [364-369](#),  
[365](#), [366](#), [367](#)  
fatal crashes among the elderly, [44](#)  
fetal alcohol syndrome, estimates, [283](#)  
fractures, incidence of, [258](#)  
hepatitis C, estimated prevalence, [206](#)  
lives saved by minimum drinking age laws, [380](#)  
lives saved by raising alcohol taxes, [387](#)  
mortality due to liver cirrhosis, [9](#)  
number of persons in treatment, [134](#)  
percent of children exposed to family alcohol  
use, [1](#)  
percent with alcohol-induced brain damage,  
[134](#)  
prevalence of alcohol abuse and dependence, [1](#),  
[30](#), [134](#)  
prevalence of liver cirrhosis, [9](#)  
price elasticity of alcohol, [342-347](#), [344](#)  
probability of alcohol dependence among  
alcohol users, based on year born, [42](#)  
victimization of intimates/strangers, [57](#)  
Steatohepatitis. *See* [Fatty liver](#)  
Stellate cells, [198](#), [203](#), [239](#)  
Stepped-care approach, [429](#), [438](#)  
Stomach cancer. *See also* [Cancer](#)  
alcohol-associated risk, [10](#)  
Stress  
biological response, [114](#)  
children of alcoholics and, [183](#)  
executive function and, [184](#)  
financial stress and drinking, [187](#)  
inconsistent findings due to time lags, [188](#)  
reduction of, [11](#), [187-188](#)  
role in alcohol abuse and dependence, [11](#)  
Stress management training, [357](#)  
Stressors  
childhood, [183](#)  
women's drinking and, [188](#)  
Striatum  
dopamine levels, [99](#)  
dopaminergic pathways, [115](#)  
oxidative stress and, [141](#)  
Stroke, [240](#), [246](#). *See also* [Cerebrovascular disease](#)  
hemorrhagic, [246](#)  
ischemic, [246](#)  
oxidative stress and, [141](#)  
protective mechanisms, [246](#)  
risk of hemorrhagic stroke, [7-8](#)  
risk of ischemic stroke, [7-8](#)  
Students Against Drunk Driving, [386](#)  
Students. *See* [Adolescents](#); [Children](#); [College](#)  
[students](#); [Monitoring the Future Study](#)  
Substance Abuse and Mental Health Services  
Administration National Household Survey,  
[31](#), [32](#), [39](#)  
Subtypes of alcoholism, [36](#), [187](#). *See also*  
[Alcohol dependence](#); [Typologies](#)  
Superoxide dismutase, [140](#)  
Support services. *See* [Treatment, treatment](#)  
[methods, supportive ancillary services](#)  
Susceptibility. *See* [Genetic susceptibility](#)  
Sweden. *See also* [Europe](#); [International](#)  
BAC limits, [383](#)  
behavioral risk factors in adolescents, [34-35](#)  
Switzerland. *See also* [Europe](#); [International](#)  
BAC limits, [382](#)  
Synaptic potentials, [70](#)  
Synaptic transmission  
alcohol effects, [78-85](#)  
described, [73-74](#)  
GABAergic, [76](#), [78](#), [82](#)  
glutamatergic, [76](#), [84](#)  
glycinergic, [78](#)  
**T**  
T-ACE questionnaire, [328](#), [329](#), [431-432](#)  
Taxes on alcohol, [341-352](#). *See also* [Economics](#);  
[Price of alcohol](#)  
alcohol consumption and, [60](#), [342-346](#)  
alcohol industry, effects on, [351](#)  
benefits and costs, [349-351](#)  
consumer response, [342-351](#), [344](#)  
current Federal rates, [341](#)  
distribution among populations, [350-351](#)  
employment, effects of alcohol taxes on, [351](#)

- heavy drinking and, [387](#)  
 optimal taxation of alcohol, [349-350](#)  
 potential benefits, [349-350](#)  
 regressivity of, [350-351](#)  
 revenues, [366, 370](#)  
 traffic fatalities and, [346-348, 387-388](#)
- T-cells, [215, 216, 217, 218, 220, 221, 223, 239](#)  
 CD4 T-cells, [218, 236](#)  
 CD8 T-cells, [218, 236](#)  
 TH1, [222-223, 225, 226, 239](#)  
 TH2, [222-223, 225, 226, 239](#)
- Teenagers. *See* [Adolescents](#)
- Temperament  
 as a risk factor, [33-35](#)
- Tennessee  
 alcohol control regulation and outlet density, [389](#)  
 DWI law enforcement, [386](#)
- TGF. *See* [Transforming growth factor beta](#)
- Thalamus, [134](#)
- Thiamine deficiency, [134](#)
- Tianeptine, [117](#)
- Tissue plasminogen activator, [245-246](#)
- T-lymphocytes. *See* [T-cells](#)
- TMI–TMIV. *See* [Transmembrane domains](#)
- TNF. *See* [Tumor necrosis factor alpha](#)
- Tobacco  
 genetic factors in alcohol and tobacco use, [171-172](#)
- Tolerance. *See* [Alcohol tolerance](#)
- Tourette syndrome, [294](#)
- tPA. *See* [Tissue plasminogen activator](#)
- Traffic accidents. *See* [Traffic crashes](#)
- Traffic crashes. *See also* [Injuries](#); [Prevention](#)  
 administrative license revocation, effects on, [381-382](#)  
 alcohol advertising, effects, [416-417](#)  
 alcohol-related, [373, 375-385, 403, 405](#)  
 BAC and, [381, 382-385, 384](#)  
 characteristics comparison, [376](#)  
 elderly and, [44](#)  
 fatalities, [1, 346-348, 375, 378, 381-382](#)  
   nighttime versus daytime, [347, 381, 416](#)  
   non-alcohol-related versus alcohol-related, [378](#)  
   underage drinkers, [347, 377, 379, 381](#)  
   victim types, [375](#)  
 reduction in, since 1982, reasons for, [375-377](#)  
 risk of, [8, 384](#)  
 seat belts and, [390-391](#)
- Transcription factors, [120-121, 153](#)
- Transcription. *See* [Gene transcription](#)
- Transforming growth factor beta, [198, 219, 239](#)
- Transgenic mice, [149, 152, 303](#)
- Translation. *See* [Gene translation](#)
- Transmembrane domains, [76, 93, 97, 101](#)
- Transmission-disequilibrium test, [175, 176](#)
- Trauma Scale questionnaire, [431](#)
- Treatment, [427-439, 444-449, 451-458](#).  
*See also* [Brief intervention](#); [Counseling](#);  
[Drug therapy](#)  
 alcohol-abusing pregnant women, [329-331, 436-437](#)  
 cost-effectiveness analysis, [355-361](#)  
 cost offsets due to treatment, [358](#)  
 costs, across settings, [356](#)  
 costs, inpatient versus outpatient, [355-356](#)  
 costs, long-term, [359-360](#)  
 DWI offender, [385](#)  
 intensity, [438, 448, 449](#)  
 level of AA attendance, [357, 445-446](#)  
 methodology for measuring costs, [360-361](#)  
 stepped-care approach, [429, 438](#)  
 treatment methods  
   behavioral marital therapy, [357, 358](#)  
   behavioral therapy, [356, 358](#)  
   brief intervention, [429-439](#)  
   cognitive-behavioral therapy, [357, 445](#)  
   community reinforcement approach, [357](#)  
   drug therapy, [357, 451-458](#)  
   motivational enhancement therapy, [357, 446, 448](#)  
   psychological approaches, [444-449](#)  
   residential milieu treatment, [357](#)  
   self-control training, [357](#)  
   social skills training, [357](#)  
   stress management training, [357](#)  
   supportive ancillary services, [446-448](#)  
   twelve-step program, [357, 445-446](#)  
 treatment outcome, [445, 446, 447, 448, 453, 457, 458](#)  
 aftercare and, [359](#)  
 inpatient versus outpatient, [355-356, 359](#)  
 length of stay, [358-359](#)  
 treatment intensity and, [444](#)  
 treatment setting, [359, 447](#)
- Treatment-seeking behavior, [173](#)
- Trends. *See* [Statistics](#)
- Tuberculosis, [214-215, 220, 224](#)
- Tumor necrosis factor alpha. *See also* [Cytokines](#);  
[Interleukins](#); [Transforming growth factor beta](#)

acetaminophen liver toxicity, [205](#)  
 defined, [239](#)  
 immune system and, [218-219](#), [219](#), [222](#)  
 malnutrition and, [202](#)  
 role in alcoholic liver disease, [198-202](#), [199](#),  
[203](#), [255](#)  
 therapeutic measures, [226](#)  
 TWEAK questionnaire, [329](#), [431-432](#)  
 Twelve-step program, [427](#), [428](#), [445-446](#)  
 Twin/family studies, [169-173](#)  
 Tylenol. *See* [Acetaminophen](#)  
 Typologies  
 alcohol dependence, [36](#)  
 Tyrosine hydroxylase gene, [176](#)

## U

Underage drinking. *See* [Adolescents, Children](#);  
[College students](#); [Minimum legal drinking  
 age laws](#); [Monitoring the Future Study](#)  
 Uniform Accounting System and Cost Reporting  
 for Substance Abuse Treatment Providers,  
[360](#)  
 Uniform Crime Report series, [60](#), [61](#)  
 United Kingdom. *See also* [Europe](#); [International](#);  
[Scotland](#)  
 BAC limits, [382](#)  
 brief intervention in family practice, [433](#)  
 U.S. Department of Veterans Affairs, [358](#), [367](#)  
 analysis of 15 treatment programs, [446](#), [454](#)  
 U.S. Vietnam Era Twin Registry, [173](#)  
 U.S. World War II Era Veteran Twin Registry, [172](#)

## V

Vascular system  
 alcohol effects, [244-248](#)  
 Vasopressin, [137](#)  
 Vehicles and tags  
 action against, [377](#), [383](#)  
 Ventral tegmental area  
 alcohol effects, [114-115](#)  
 dopamine levels, [99](#), [122](#)  
 Ventricular tachycardia, [242](#)  
 Vesicle fusion, [73](#)  
 Veterans, [454](#)  
 Victim Impact Panels, [385](#)  
 Victims. *See* [Crime victims](#)  
 Violence. *See also* [Crime victims](#); [Domestic violence](#);  
[Offenders, criminal](#)

alcohol and, [54-63](#), [407](#)  
 alcohol consumption and homicide, [60](#)  
 alcohol versus other drug involvement, [55-56](#)  
 alcohol-related, percentage, [2](#), [56](#)  
 amount consumed and seriousness of crime, [58](#)  
 availability of alcohol and, [59-61](#)  
 BAC and homicide, [56](#)  
 environmental influences, [59-61](#)  
 frontal brain lobes and, [141](#)  
 individual level studies, [55-59](#)  
 drinking by crime victims, [58-59](#)  
 drinking by criminal offenders, [55-58](#), [56](#)  
 intoxicated aggression, factors in, [62](#)  
 personality characteristics, [13](#), [57-58](#)  
 research methodologies, [55](#)  
 severity of violence, [57](#)  
 sexual assault and, [58-59](#)  
 social norms and, [61-62](#)  
 theoretical models, [61-63](#)  
 youth homicide and minimum legal drinking  
 age, [61](#)  
 VIP. *See* [Victim Impact Panels](#)  
 Vitamin A, [200](#), [309](#)  
 Vitamin C, [276](#)  
 Vitamin D, [262-263](#)  
 Vitamin E, [200](#)

## W

Waiter. *See* [Server](#)  
 Waitress. *See* [Server](#)  
 Warning labels  
 acetaminophen, [206](#)  
 alcoholic beverage containers, [327](#)  
 Washington  
 action against vehicles and tags, [383](#)  
 WAY 100635, [457](#)  
 Wernicke's encephalopathy, [134-135](#), [139](#).  
*See also* [Encephalopathy](#)  
 Wernicke-Korsakoff syndrome, [134-135](#), [136](#), [137](#),  
[138](#)  
 West Virginia  
 alcohol sales, [389](#)  
 White blood cells. *See* [Lymphocytes](#)  
 Whites. *See* [Caucasians](#)  
 WHO. *See* [World Health Organization](#)  
 Wife  
 intervention by, [390](#)  
 Wine. *See also* [Beer](#); [Distilled spirits](#)  
 advertisements and market share, [417](#)

Wisconsin

Communities Mobilizing for Change on Alcohol, [401](#)

Project GOAL, [437](#)

Withdrawal. *See* [Alcohol withdrawal syndrome](#)

Women. *See also* [Alcohol-related neurodevelopmental disorders](#); [Fetal alcohol effects](#); [Fetal alcohol syndrome](#); [Gender differences](#); [Maternal alcohol consumption](#)

age of drinking onset, [41](#)

alcohol metabolism in women, [254-255](#), [256](#), [274](#)

*Alcp2*, [164](#)

brief intervention and pregnant women, [436-437](#)

drinking patterns/levels, [254](#)

hormone replacement therapy, [264](#), [274](#)

maternal drinking patterns and fetal alcohol effects, [301-302](#)

maternal risk factors and FAS, [324](#), [328](#)

risk of brain damage, [138](#), [253-254](#)

risk of breast cancer, [273-278](#)

risk of cardiovascular disease, [253](#), [254](#)

risk of liver disease, [9](#), [253](#)

risk of myopathy, [253](#)

risk of osteoporosis, [258](#), [259](#), [260](#)

risk of stroke, [8](#)

sexual assault and, [58-59](#)

vulnerability to alcohol's health effects, [197](#), [253-256](#)

Women's Health Study, [10](#)

Workplace accidents

due to employee alcohol problems, [370](#)

World Health Organization, [431](#), [435](#)

## X

*Xenopus* oocytes, [90](#), [93](#), [94](#), [95](#), [97](#), [98](#)

## Y

Years of potential life lost

defined, [5](#)

contrasted with overall mortality, [14](#)

Young adults

alcohol demand, [344-346](#)

executive functioning and alcohol consumption, [184](#)

genetics of alcohol and tobacco use, [172](#)

patterns in use, [186-187](#)

response to alcohol price changes, [344-346](#)

risks of alcohol use, [17](#)

## Z

Zero Tolerance laws, [381](#). *See also* [Blood alcohol concentration](#); [DWI laws](#); [Minimum legal drinking age laws](#)

Zoloft. *See* [Sertraline](#)

Zoning, [404](#), [405](#)